US20190159897A1 - Percutaneously Deliverable Heart Valve and Methods Associated Therewith - Google Patents
Percutaneously Deliverable Heart Valve and Methods Associated Therewith Download PDFInfo
- Publication number
- US20190159897A1 US20190159897A1 US16/265,573 US201916265573A US2019159897A1 US 20190159897 A1 US20190159897 A1 US 20190159897A1 US 201916265573 A US201916265573 A US 201916265573A US 2019159897 A1 US2019159897 A1 US 2019159897A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- heart valve
- valve
- frame
- assembly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003709 heart valve Anatomy 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title description 32
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 46
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 11
- 230000007246 mechanism Effects 0.000 claims abstract description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 222
- 210000004379 membrane Anatomy 0.000 description 34
- 239000012528 membrane Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 10
- 241000150258 Prospect Hill orthohantavirus Species 0.000 description 9
- 210000003516 pericardium Anatomy 0.000 description 9
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 210000001765 aortic valve Anatomy 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000004513 sizing Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000002788 crimping Methods 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000003102 pulmonary valve Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 0 C*([Zn]CCN*)I Chemical compound C*([Zn]CCN*)I 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- -1 that is Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 208000016258 weakness Diseases 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0095—Packages or dispensers for prostheses or other implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/243—Deployment by mechanical expansion
- A61F2/2433—Deployment by mechanical expansion using balloon catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
- A61F2/2466—Delivery devices therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0075—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
- Y10T29/49908—Joining by deforming
Definitions
- the present invention relates to the field of medical devices, and more particularly, to a percutaneously deliverable heart valve and a method of making a percutaneously deliverable heart valve.
- Heart valve disease is a common degenerative condition that compromises physiologic function and causes limiting symptoms and threat to life in millions of patients all over the world.
- Heart valves There are various underlying causes, but malfunction of heart valves is ultimately expressed as insufficient conduction of blood through the plane of the valve due to narrowing of the anatomic pathway (stenosis), or as incompetent closure that allows blood to return back through the valve again, thereby reducing the effective forward conduction of blood through the valve (insufficiency or regurgitation).
- These hemodynamic states lead to 1) deficiency of cardiac output and 2) adverse loads on the pumping chambers of the heart, both of which in turn lead to functional compromise of the patient and often premature death unless effectively corrected.
- Heart valve surgery is performed in hundreds of thousands of cases yearly world-wide, but carries a high burden of cost, morbidity, and mortality, especially in susceptible patients who may be elderly or otherwise physiologically compromised by collateral disease. Further, the costs and resource requirements of the surgical enterprise restrict the availability of heart valve replacement to many more patients all over the world.
- PHVR PHVR
- the application of PHVR thus far has been challenged by the technical difficulties of the implantation sequence—especially in the aortic valve position.
- the technique for available devices is limited by the large caliber of the devices and their delivery catheters; often, if it can be done at all in some smaller arteries, open surgical exposure and management of the femoral artery is required to insert the 18-24 French (6-8 mm diameter) systems, and their bulkiness inside the central arteries can threaten the safety of the delivery sequence. Further, access site bleeding complications form a significant part of the adverse events of the procedures.
- the current PHV designs comprise a biological membrane forming the operating leaflets of the valve, attached within a metal frame, that is then collapsed onto a delivery catheter or balloon, and then constrained within an outer sheath. After an initial dilation of the diseased valve with a large balloon, this assembly is then advanced to the plane of the valve and deployed by self-expansion or by balloon expansion.
- the effective caliber of the valve delivery system is determined by the total bulk of each coaxially mounted component.
- the bulk of the PHV itself is determined by the diameter of the frame and by the thickness, stiffness, and particular arrangement of the inner membrane forming the operating leaflets of the valve.
- the characteristic thickness of current PHV membranes is thus a limiting factor in the ultimate delivery profile of the PHV.
- Such characteristic membrane thickness is, in turn, a result of the methods by which it is processed and ultimately delivered for use.
- glutaraldehyde fixation for protein cross-linking
- Requirements for strength and durability have determined the most useful ranges for tissue thickness and cross-linking while typically imposing countervailing stiffness and brittleness. Subsequent hydration in suitable solutions improves these characteristics, but the hydrated membrane by this means also gains thickness.
- PHVs are delivered for use “wet” in a preservative solution, they have to be treated prior to insertion with a series of cleansing and hydrating solutions. Once this is completed, the PHVs have to be mounted on their delivery catheters. Special crimping and mounting tools are needed in the case of the balloon-expandable Edwards Sapien valve, for example. Accordingly, there is a need to address the shortcomings discussed above.
- an assembly configured for replacing an aortic or pulmonary heart valve in a human patient.
- the assembly comprises a transcatheter, prosthetic aortic or pulmonary heart valve.
- the transcatheter, prosthetic aortic or pulmonary heart valve may comprise a frame that is expandable and collapsible, and a tissue leaflet assembly sutured directly to the frame.
- the tissue leaflet assembly may include three substantially dry leaflets formed from a treated mammalian pericardial tissue that has been treated with glutaraldehyde and glycerol, and that has a thickness of between about 50 to 300 ⁇ m.
- the assembly may further comprise a percutaneously insertable valve delivery mechanism including a including a balloon catheter of size 12 to 14 French, and that includes a guidewire lumen.
- the transcatheter, prosthetic aortic or pulmonary heart valve may be releasably and coaxially mounted onto the balloon catheter of the percutaneously insertable valve delivery mechanism.
- the assembly may also include a sterile package containing the transcatheter, prosthetic aortic or pulmonary heart valve that is releasably and coaxially mounted onto the balloon catheter.
- the frame may comprise a stent.
- the treated mammalian pericardial tissue may have an ultimate tensile strength of greater than about 12 MegaPascals.
- the treated mammalian pericardial tissue may not include a matrix that has been exposed to a polymer infiltrate.
- the treated mammalian pericardial tissue may have been treated with distilled water. Additionally and/or alternatively, the treated mammalian pericardial tissue may have been treated with isopropyl alcohol.
- FIG. 1 is a flow chart of a method associated with at least of one embodiment of the present invention
- FIGS. 2A-2B are a flow chart illustrating elements of the tissue preparation
- FIG. 3 is a flow chart illustrating elements of the drying and sizing
- FIG. 4 is a flow chart illustrating elements of the valve construction with attachment of tissue membrane leaflets to a frame
- FIG. 5 is a flow chart illustrating elements of the mounting of the valve into a delivery system
- FIG. 6 is a flow chart illustrating elements of the ensheathing, sterilization, and packaging
- FIG. 7 is a flow chart illustrating elements of the delivery of the valve into a patient
- FIG. 8A is a view of a one-piece section of tissue prior to being folded
- FIG. 8B is a view of two (of three) separate pieces of tissue after folding (detailed below);
- FIG. 8C is a view of the two pieces of tissue shown in FIG. 8B after being sutured together at the pleat formed after folding (detailed below);
- FIG. 8D is a view of a tissue blank with the line of primary fold shown using a dashed line;
- FIG. 8E is a perspective view of the tissue blank being folded along the primary fold line
- FIG. 8F is a 2-part figure showing the pleats fold lines and pleats after folding
- FIG. 8G is a detail perspective view of a single pleat shown in FIG. 8F ;
- FIG. 8H is a perspective schematic view of a folded and seamed tissue leaflet assembly
- FIG. 8I is a perspective schematic view of a frame
- FIG. 8J is a perspective schematic view of the frame of FIG. 8I with the tissue leaflet assembly of FIG. 8H attached thereto;
- FIG. 8K is side elevation schematic view of the device shown in FIG. 8J ;
- FIG. 8L is an end schematic view of the frame and tissue leaflet assembly attached thereto;
- FIG. 9 is a graph that shows actual stress-strain test results for five tissue samples prepared in accordance with at least one embodiment
- FIG. 10 is a schematic of a portion of a catheter with a percutaneously deliverable heart valve mounted thereto;
- FIG. 11A is a photo of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a partially open orientation;
- FIG. 11B is a drawing of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation;
- FIG. 11C is a side cutaway view of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation;
- FIG. 11D is another side cutaway view of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation;
- FIG. 12 is a photo of valve tissue after testing through 30,000,000 cycles of pumping used to model human heart conditions, wherein the photo shows a smooth uniform surface
- FIG. 13 is a drawing of a surgeon holding a premounted percutaneously deliverable heart valve associated with a catheter and residing within sterile packaging;
- FIG. 14 is a schematic of a simplified cutaway view of a human heart, including heart valves that may be targeted for receiving an embodiment of an implantable prosthetic heart valve;
- FIG. 15 is a schematic of a human aorta receiving a catheter with an implantable prosthetic heart valve mounted thereto;
- FIG. 16 is a schematic of a human aorta with the implanted prosthetic heart valve implanted at the site of the original diseased aortic valve;
- FIG. 17 is a schematic of a prosthetic heart valve and a mandrel of a delivery catheter.
- Embodiments of the one or more inventions described herein include one or more devices, assemblies and/or methods related to a prosthetic heart valve.
- a prosthetic heart valve in accordance with at least one embodiment described herein can be surgically implanted, such as by percutaneous, trans-catheter delivery, to the implantation site within the patient.
- One or more embodiments of the prosthetic heart valves described herein have application for at least aortic and pulmonary valve positions, including for structural defects and diseased valves.
- biocompatible material is attached within a frame to form an implantable prosthetic heart valve, and then at a later time, the implantable prosthetic heart valve is implanted within a patient, such as by way of a percutaneous, trans-catheter delivery mechanism. Once implanted, the prosthetic heart valve serves to regulate the flow of blood associated with the patient's heart by allowing forward blood flow and substantially preventing backflow or valvular regurgitation.
- the prosthetic heart valve preparation and delivery method 100 generally includes a plurality of procedures to include tissue preparation at 200 , drying at 300 , tissue leaflet assembly construction and attachment to frame at 400 to form an implantable prosthetic heart valve, mounting of the prosthetic heart valve (that is, the frame with the tissue leaflet assembly) into a delivery system at 500 , ensheathing, sterilizing and packaging the delivery system including the prosthetic heart valve at 600 , and finally, delivering the prosthetic heart valve into the patient at 700 . Further detail of the prosthetic heart valve preparation and delivery method 100 is provided below.
- At least one or more embodiments described herein include a relatively thin tissue component.
- the tissue has a thickness of approximately 50-150 ⁇ m, and further possesses characteristics of pliability and resistance to calcification after implantation.
- the relatively thin nature of the tissue used in the implantable prosthetic heart valve assists with biocompatibility.
- the relatively thin tissue component thereby provides for a relatively low mass. As a result, an implantable prosthetic heart valve using the tissue can accelerate to a relatively high heart rate in beats per minute with competent function.
- Tissue suitable for use in the one or more prosthetic heart valves and/or one or more assemblies described herein is relatively thin and can generally be considered to be a membrane.
- a membrane can generally be considered to be a membrane.
- both natural and synthetic types of materials may be used to form a leaflet assembly of a prosthetic heart valves. Accordingly, it is to be understood that although treated pericardium tissue is described as a suitable material for use in the leaflet assembly of a prosthetic heart valve of one or more embodiments described herein, material other than xenograft tissue membrane can be used, and indeed, xenograft tissue membrane other than pericardium tissue can be used. More specifically, synthetic materials may include, but are not limited to, PTFE, PET, Dacron, and nylon.
- xenograft tissue membrane may include, but is not limited to, membrane material from the intestine, lung and brain. Suitable material may also comprise allograft material, that is, material from human sources. The listing of possible materials is for exemplary purposes and shall not be considered limiting.
- pericardium tissue such as porcine or bovine pericardium tissue
- pericardium tissue is harvested at 204 and then processed to serve as the biocompatible tissue for association with a frame, such as by attaching within a frame.
- the pericardium tissue is cleaned and decellularized at 208 . More particularly, in at least one embodiment the tissue is initially cleaned with distilled water using gentle rubbing and hydrodynamic pressure at 208 in order to remove adherent non-pericardial and non-collagenous tissue.
- the hydrodynamic pressure at 208 is provided by spraying the tissue with a relatively weak stream of liquid to remove at least some of the non-collagenous material associated with the tissue.
- the rinsing at 208 is to achieve effective decellularization of the pericardium tissue through osmotic shock.
- the thickness of the tissue in the cleaned condition varies from about 50 to 500 micrometers, depending on the source of raw tissue. Cleaning preferably continues until there is no visible adherent non-pericardial or non-collagenous tissue.
- the tissue then undergoes optional additional removal of lipids at 220 to further treat the tissue for preventing immunologic response and calcification. More particularly, the tissue first optionally undergoes a 100% glycerol pretreatment at 224 while being positioned on a flat surface (e.g., an acrylic plate), after which the tissue becomes nearly transparent.
- a flat surface e.g., an acrylic plate
- the tissue optionally undergoes a “thermophotonic” process.
- the tissue is optionally exposed to light energy for additional removal of lipids and for initial cross-linking of the collagen.
- a 25-100 watt incandescent light source and more preferably, a 50 watt incandescent light source with a flat radiant face is employed at a distance of about 10 centimeters from the tissue surface, typically requiring 15 minutes of exposure before further visible separation of lipid droplets from the tissue stops.
- the tissue is then cleaned again in secondary cleaning at 232 . More particularly, at 236 the tissue is again rinsed with distilled water. Thereafter, at 240 the tissue is rinsed with 25% isopropyl alcohol for periods of several hours to several days and weeks, depending on the desired tissue properties of pliability and tensile strength.
- tissue has been successfully prepared by rinsing with 25% isopropyl alcohol for a period of 7 days, and after further treatment steps described herein, provided an ultimate tensile strength of greater than 25 MegaPascals.
- tissue pliability and tensile strength is sought for purposes of producing a material having property characteristics suitable for being physically manipulated to form a tissue leaflet assembly or other configuration appropriate for attaching with a frame, while providing a tissue material that will operate properly once implanted.
- These techniques are intended to conserve and preserve collagen fibers, minimizing damage to the tissue and improving tissue characteristics.
- the preparation and fixation techniques produce tissue membrane material that may be rendered and used at lesser thickness than typically rendered in the prior art. Thinner membranes are more pliable, but with conventional preparation techniques the tensile strength of the tissue is sacrificed.
- the preparation techniques described herein have produced membranes that have as much as three times the tensile strength of a commercial product of the prior art.
- tissue leaflet assembly having a low profile with appropriate durability, even in a substantially dry state.
- the tissue possesses a relatively high tensile strength.
- embodiments of tissue prepared as described herein provide a tissue with a tensile strength of approximately three times the tensile strength of current pericardial valve tissue, such as on the order of approximately 25 MegaPascals, thereby providing about 2000 times the physiologic load strength for valve tissue.
- testing of an embodiment of an implantable prosthetic heart valve made with tissue prepared as described herein and under a static load of greater than approximately 250 mmHg showed less than approximately 14% leakage, wherein such results are generally considered superior to surgical tissue valve prostheses.
- ethanol may be used in its place as an alternative, although resulting tissue properties may vary.
- stress-strain curve results for five different tissue samples prepared in accordance with an embodiment are shown.
- the yield stress or ultimate tensile strength was obtained by mounting strips of tissue fixed at the ends in a linear force tester and increasing the length by 0.3 mm/sec while recording resultant force (tension) until the material ruptured or separated entirely; these measurements were then used to calculate the stress-strain curves depicted in FIG. 9 .
- the yield stress or ultimate tensile strength of the various tissue samples varied from about 30 to about 50 MegaPascals. More particularly, for each curve shown in FIG. 9 , the testing procedures were the same. That is, each of the curves shown pertain to separate pieces of tissue that were subjected to the same test.
- the results show a minimum ultimate tensile strength of 30 MegaPascals, with a range up to 50 MegaPascals. Accordingly, the illustrated test results demonstrate consistency of the ultimate tensile strength results for the tissue treatment process.
- the tissue is rinsed with distilled water at 244 as a final cleaning step and for rehydration.
- fixation for collagen cross-linking at 248 is achieved by performing at least one of the following:
- step a followed by step b steps a followed by step c; and step a followed by step d.
- heat-shrink testing may be conducted on tissue samples to correlate the effectiveness of protein cross-linking.
- results of heat-shrink testing performed on one or more samples of tissue prepared in accordance with at least one embodiment using formalin showed that the tissue had a shrink temperature of 90° C. This compares favorably with samples prepared using glutaraldehyde, wherein the shrink temperature was 80° C.
- formalin is a suitable variant of fixation. It is noted that formalin was generally abandoned by the field, largely because of material properties that were unfavorable and because of inadequate or unstable protein cross-linking. Such problems have been overcome through the pretreatments described herein, allowing production of tissue with strength, pliability, and durability in a relatively thin membrane.
- tissue characteristics imparted by the tissue preparation process facilitate formation of a construct having a relatively low-profile, which also thereby facilitates dry packaging of the prosthetic heart valve.
- the same advantages are also achieved using the pretreatments when using a glutaraldehyde process.
- an alcohol post-fixation treatment at 252 is preferably performed by rinsing the tissue in distilled water at 256 , and then at 260 rinsing the tissue in 25% isopropyl alcohol for between about 30 minutes to 14 days or more at between about 0 to 37° C., and more preferably, for at least about 7 days at 20° C.
- the tissue undergoes a rinsing with distilled water.
- treatment of the tissue does not include contact and/or exposure to a polymer to infiltrate and/or encapsulate tissue fibers of the tissue.
- the drying process at 300 is performed after the tissue preparation at 200 .
- the tissue is dried under a load. More particularly, for the tissue drying at 304 , the tissue is placed minimally stretched flat (that is, stretched just enough to eliminate visible wrinkles and bubbles) on a flat surface (e.g., a polymer or acrylic sheet) at 308 , and held fixed at its edges at 312 .
- a flat surface e.g., a polymer or acrylic sheet
- the joined tissue and underlying sheet are then set in a slight curve.
- the tension maintains the substantially flat structure of the tissue as it dries, thereby mitigating or preventing excessive shrinkage, wrinkling, and/or curling at the edges, and also making the rate of drying more uniform across the surface of the tissue because of the surface tension between the plate and the tissue.
- the tissue is dried while compressed between acrylic plates.
- the temperature is held at between about 4 to 37° C., and more preferably, between about 20 to 37° C. (i.e., approximately room temperature to normal human body temperature), and more preferably, at about 20° C.
- the drying process is performed in substantially dark conditions (i.e., substantially no visible light) for between about 6 hours to 5 days, and more preferably, for about 72 hours.
- the tissue is dried in dark conditions at a temperature of about 20° C. for between about 6 hours to 5 days, and more preferably, for about 72 hours.
- a temperature of about 20° C. for between about 6 hours to 5 days, and more preferably, for about 72 hours.
- drying the tissue while the tissue is compressed between plates requires a longer period of time.
- the tissue lots are inspected at 316 , such as by stereomicroscopy, to identify and discard those with defects or discontinuities of the fiber matrix.
- the preferential fiber direction for each piece is identified to determine the necessary orientation of the free edge of the pieces that will form the valve leaflets.
- the tissue may be trimmed or otherwise sized in optional sizing at 320 , such as by cutting the tissue into an appropriately sized and shaped sheet for valve formation.
- cutting of the tissue membrane is oriented so that the resulting free edge of the leaflet is parallel to the preferential fiber direction of the tissue membrane.
- the free edge of the leaflets may also be cut with a parabolic or other curved profile to compensate for the downward angle from the commissural leaflet attachment point to the central coaptation point and to increase the total contact surface between the coapting leaflets.
- This approach minimizes focal weaknesses in the operating margins of the leaflet assembly and advantageously distributes the principal loading forces of the operating valve along the long axis of the collagen fibers. As a result, the tissue is resistant to surface fracture and fraying.
- optional sizing at 320 is performed after the drying at 304 and inspection at 316 .
- tissue generated from one or more of the tissue preparation procedures described herein may be used for a variety of devices or uses, and that use in a prosthetic heart valve is but one possible application for utilizing the tissue.
- the tissue may be used in a shunt, or as graft material for repair or modification of one or more human organs, including the heart and its blood vessels.
- the tissue may be used as a pericardial membrane patch for repair of congenital heart defects.
- the tissue also has application as a prosthetic tissue in tendon and ligament replacement, and as a tissue product for wound management.
- the tissue may be configured in a variety of ways and attached to a frame in a variety of ways.
- the prepared tissue is formed into a tissue leaflet assembly at 404 by folding the tissue at 408 , preferably while the tissue is in a dry state, to form at least a portion of the tissue leaflet assembly.
- a completed tissue leaflet assembly may be formed of a single monolithic piece of tissue 800 , such as that shown in FIG. 8A , or alternatively, as shown in FIGS.
- the seams 804 are preferably situated at overlapping portions of pleats 832 of the plurality of tissue pieces 802 .
- a single monolithic piece of tissue 800 or a plurality of tissue pieces 802 may be used to form a prosthetic heart valve, wherein the tissue leaflet assembly is not a folded construct.
- a plurality of separate tissue pieces may each be attached to a frame (such as by suturing) to form a prosthetic heart valve. Thereafter, whether the prosthetic heart valve is made of a folded tissue leaflet assembly or a plurality of separate tissue pieces attached to a frame, the resulting prosthetic heart valve may then be further manipulated for delivery as a dry prosthetic heart valve.
- tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that includes a frame, and that may be implanted by a “trans-apical” approach in which the prosthetic heart valve is surgically inserted through the chest wall and the apex of the heart.
- tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that does not include a frame, and is not delivered via a catheter, but rather, is implanted via a surgical opening through the patient's chest.
- the prosthetic heart valve may be packaged for delivery as a dry prosthetic heart valve.
- tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that includes a frame, but that is not delivered via a catheter, but rather, is implanted via a surgical opening through the patient's chest.
- the prosthetic heart valve may be packaged for delivery as a dry prosthetic heart valve.
- tissue may be implanted in a “wet” or hydrated state.
- a prosthetic heart valve utilizing a prepared tissue described herein may be packaged for delivery as a hydrated prosthetic heart valve.
- the tissue preparation process may include drying the tissue so that it may be manipulated more easily, the tissue may then be hydrated at a later point in time prior to implantation, and it may be maintained in a hydrated condition up to and including packaging, delivery and implantation into a patient.
- Advantages associated with using a folded tissue leaflet assembly include that a folded structure allows a relatively thin membrane to be used by avoiding suture lines in loaded, dynamically active surfaces. Accordingly, a sutureless leaflet assembly preserves long-term integrity.
- a prosthetic heart valve that does not include a folded tissue leaflet assembly is encompassed by one or more embodiments described herein.
- FIGS. 8D-8L for a prosthetic heart valve that includes a tissue leaflet assembly formed of a folded tissue membrane, the folding sequence for the tissue is shown for configuring the tissue into a completed tissue leaflet assembly. More particularly, a tissue blank 808 is shown in FIG. 8D , wherein the tissue blank 808 is a single monolithic piece of tissue 800 . Depending upon the size requirements for a given tissue leaflet assembly, a line of primary fold or fold line 812 (shown as a dashed line) is visualized for the tissue blank 808 . As shown in FIG.
- the primary fold 814 is achieved along the fold line 812 by folding the bottom edge 816 of the tissue blank 808 toward the top edge 820 , but leaving a cuff portion 824 along the upper portion 828 of the tissue blank 808 .
- the direction of top and bottom are relative to each other and are used as a convenience for describing the folding sequence, wherein such directions correspond to the orientation of the page illustrating the drawings.
- the folding geometry of FIGS. 8D-8L forms cuffs 824 that are continuous with the leaflets, thereby reducing the risk of aortic insufficiency or leakage.
- FIG. 8F after folding the tissue blank 808 along fold line 812 to form primary fold 814 , pleats are formed by folding the tissue along its length.
- FIG. 8F three pleats 832 a , 832 b , and 832 c are shown.
- FIG. 8G illustrates a detail drawing of a single pleat 832 representative of one of pleats 832 a - c .
- the inner leaflet layer free edge 836 is shown, as is the valve sinus 840 and the commissure folds 844 .
- FIG. 8H shows a schematic perspective drawing of tissue leaflet assembly 848 , wherein the pleated tissue construct shown in the bottom half of FIG. 8F is seamed, such as along seam 850 , to form a substantially tubular construct.
- the folded tissue leaflet assembly 848 is maintained dry or is partially hydrated prior to mounting the tissue leaflet assembly in a frame.
- the tissue leaflet assembly 848 is then attached within a frame, such as frame 852 shown in FIG. 8I .
- the tissue leaflet assembly 848 attached within a frame 852 forms an implantable prosthetic heart valve 860 , such as that shown in the schematic perspective drawing of FIG. 8J , side elevation view FIG. 8K , as well as that shown in the photo of FIG. 11A , and drawing of FIG. 11B .
- FIG. 8K illustrates possible suture points 864 where the tissue leaflet assembly 848 can be sutured to the frame 852 . That is, the tissue leaflet assembly 848 may be attached within the frame 852 , such as by suturing the outer layer of the tissue leaflet assembly 848 to the frame.
- the term “attached” means that the tissue leaflet assembly 848 is secured to the frame 852 , although the inner leaflet layer free edges 836 are able to readily move during operation of the prosthetic heart valve 860 .
- FIG. 11C a cutaway side elevation view of a prosthetic heart valve 860 that includes a frame 852 with a tissue leaflet assembly 848 attached therein is shown.
- the tissue membrane leaflet assembly 848 is disposed coaxially within the frame 852 .
- the valve 860 is illustrated in the closed position with the leaflet free edges 836 in at least partial contact with each other.
- An arc 1112 of the leaflet free edges 836 (out of plane of the cutaway view) is continuous with pleats 832 at the radial edge of the tissue leaflet assembly 848 , and may be seen in the alternate view shown in FIG. 8L .
- the tissue membrane leaflet assembly 848 is attached to the frame 852 along the axially oriented membrane pleats 832 , as illustrated again in FIG. 8L .
- the extended cuff layer is attached circumferentially at the distal edge 1104 of the frame 852 .
- continuous suture attachment 1108 may be used to attach the extended cuff layer to the distal edge 1104 .
- FIG. 11D an embodiment is shown wherein the cuff layer is not extended distally to the distal edge 1104 of the frame 852 .
- the distal edge of the cuff layer is attached circumferentially to an inner aspect of the frame 852 , such as along those possible suture points 864 illustrated in FIG. 8K .
- a distal portion 1116 of the frame 852 does not include any portion of the tissue leaflet assembly 848 , such as the cuff layer.
- the valve 860 in the closed position the leaflet free edges 836 still at least partially contact each other.
- FIG. 8L an end view of the prosthetic heart valve is shown.
- the pleats 832 are used as the portion of the tissue leaflet assembly 848 to attach to the frame 852 .
- the outer cuff layer is attached to the frame members of frame 852 .
- the cusps 868 formed by the inner leaflet layer are generally situated as depicted in FIG. 8L .
- FIG. 12 is a photo of the tissue leaflets of a prosthetic heart valve after 30,000,000 cycles of testing to model performance if associated with a human heart. In testing, the prosthetic heart valve 860 has demonstrated a natural opening gradient of approximately 5 mmHg.
- tissue leaflet assembly 848 described and shown herein is but one possible construct for forming a flow control mechanism that can be attached to a frame to regulate the flow of blood in a patient's vascular system upon deployment. That is, the illustrated tissue leaflet assembly 848 is provided by way of example and not limitation, and in no way should be interpreted to limit the geometries of membrane leaflet assemblies that can be used to regulate fluid flow. Accordingly, other leaflet configurations and constructs are considered encompassed by claims directed to or otherwise including premounted percutaneously deliverable valves.
- the frame 852 may be a stent or a structure having similarities to a stent.
- the frame 852 essentially serves as a holding mechanism for the tissue leaflet assembly 848 that can then be inserted percutaneously into a patient, wherein the frame 852 serves as a way to anchor the folded tissue leaflet assembly 848 to a vascular portion (e.g., in situ arterial tissue) of the patient.
- a vascular portion e.g., in situ arterial tissue
- the tissue leaflet assembly 848 is inserted into a frame 852 .
- the frame 852 may comprise a balloon-expandable frame, or alternatively, at 424 b a self-expanding frame may be used.
- the folded tissue leaflet assembly 848 is attached to the frame 852 , such as by suturing the tissue leaflet assembly 848 to the frame 852 to form an implantable prosthetic heart valve 860 , such as that shown in FIG. 8L .
- the prosthetic heart valve 860 is fully hydrated for inspection and testing. Thereafter, the fully constructed implantable prosthetic heart valve 860 may be dried and maintained in a substantially dry condition.
- tissue 800 suitable for implanting in a human, wherein the implantable tissue may be allowed to dry prior to implanting, or it may be hydrated prior to implanting.
- tissue 800 is suitable for use in forming a tissue leaflet assembly 848 for use in a prosthetic heart valve, including an implantable prosthetic heart valve 860 that can be implanted with its tissue leaflet assembly in a dry state, or with its tissue leaflet assembly in a partially or fully hydrated state.
- One or more of the embodiments of the tissue leaflet assemblies described herein may be implanted into the patient using a balloon-expandable frame or a self-expanding frame.
- Expandable frames are generally conveyed to the site of the target valve on balloon catheters.
- the expandable frame is positioned in a compressed configuration along the delivery device, for example crimped onto the balloon of a balloon catheter that is part of the delivery device intended for coaxial mounting on a guidewire.
- the expandable frame is expanded by the delivery device.
- a self-expanding frame commonly a sheath is retracted, allowing expansion of the self-expanding frame.
- the frame comprises a metal alloy frame possessing a high strain design tolerance that is compressible to a relatively small diameter.
- the implantable prosthetic heart valve 860 allows standard retrograde arterial aortic delivery via femoral artery insertion, without surgical cutdown or general anesthesia. This is achieved by providing the prosthetic heart valve on a premounted delivery system with the tissue leaflet assembly or tissue membrane construct in a substantially dry condition.
- a dry tissue membrane has substantially less mass than a wet membrane.
- a substantially dry pericardium tissue prepared by one or more of the present embodiments has approximately 30% of the mass of a wet pericardium tissue, and marked reduction in profile and packing volume, thereby achieving a relatively low profile and making it suitable for implantation in greater number of patients, especially those having small diameter vascular systems.
- a dry prosthetic heart valve does not require storage and transport in preservative.
- a dry prosthetic heart valve can be mounted on a delivery catheter at its location of manufacture, which allows for pre-packaging of an integrated delivery system.
- the term “mounted” means that the prosthetic heart valve 860 is temporarily associated with the delivery catheter. Together with a relatively low profile, embodiments of the prosthetic heart valve thereby offer reliability and convenience because the implantable prosthetic heart valve 860 is pre-mounted upon its delivery catheter and forms part of a pre-packaged delivery system.
- a dry prosthetic heart valve does not require rinsing, rehydration, or mounting in a catheterization lab. Therefore, a dry prosthetic heart valve can be inserted directly from package into the patient's body at a critical time during the procedure. Advantageously, this avoids procedure time, manipulation, and errors of mounting, crimping, and orienting catheters and sheaths.
- the dry prosthetic heart valve is inserted and delivered by balloon catheter expansion in the plane of the target valve in the standard way and the dry prosthetic heart valve begins to function immediately, even without specific steps to rehydrate the tissue membrane portion of the heart valve from its dry state, with hydration of the tissue membrane subsequently occurring rapidly and naturally in the body. More particularly, hydration of the tissue membrane portion occurs rapidly and begins with simple preparatory flushing of catheter lumens with saline. Thereafter, hydration continues with device insertion and dwelling into the central blood vessels, and completes naturally after deployment in the patient's body.
- the low profile of the implantable prosthetic valve is particularly advantageous for patient's having relatively small diameter vascular systems.
- Table 1 provides aortic and pulmonary valve prosthesis sizing.
- the femoral artery has a diameter of between about 5-8 mm. Accordingly, it is apparent that embodiments of the collapsed implantable prosthetic heart valves 860 described herein offer a low profile that enables a larger group of patients to qualify for receiving an implantable prosthetic heart valve 860 . As a result of the sizing advantages offered by one or more embodiments of implantable prosthetic heart valves 860 described herein, virtually no candidate patients would be excluded from treatment with an implantable prosthetic heart valve 860 without open heart surgery and without general anesthesia on the basis of inadequate femoral blood vessel access caliber.
- implantable prosthetic heart valve 860 described herein feature a scalable construct, wherein the implantable prosthetic heart valves 860 can be produced to accommodate target valve diameters ranging between 6-35 mm, and wherein the implantable prosthetic heart valves 860 offer consistent function using fundamentally a single design.
- an implantable prosthetic heart valve 860 (also referred to herein as a percutaneously deliverable heart valve) is collapsed.
- the initial phase of collapsing the percutaneously deliverable heart valve is executed with the tissue membrane in a hydrated condition. That is, since the percutaneously deliverable heart valve 860 includes the frame 852 with the tissue leaflet assembly 848 attached within the frame 852 , the percutaneously deliverable heart valve 860 is collapsed down as an integral unit.
- an axial puller may be utilized to collapse down the frame 852 of the percutaneously deliverable heart valve 860 without the application of force directly to the sides of the frame 852 .
- This procedure offers the advantage of preserving the cell structure of the frame 852 while also maintaining the orientation of the leaflets of the tissue leaflet assembly 848 as the percutaneously deliverable heart valve 860 is compressed. The proper orientation and disposition of the leaflets is facilitated by the hydrated state of the leaflets. This assists in preventing tissue prolapse or bulging of the tissue 800 or 802 through the frame 852 .
- this technique reduces recompression strain on the metal frame 852 (e.g., a stent) that can tend to compromise fatigue life of the frame 852 .
- This technique also tends to promote the circumferentially uniform collapsing of cells in the frame 852 , thereby mitigating bunching of the tissue that forms the tissue leaflet assembly 848 of the percutaneously deliverable heart valve 860 .
- the sides are forced to collapse by providing a radial compression force to the frame and may be assisted by axial traction force.
- the percutaneously deliverable heart valve 860 i.e., the frame 852 with the tissue leaflet assembly 848 attached thereto
- the delivery mandrel 1704 as best seen in FIG. 17
- the mounting segment is then extended out the end of the sheath.
- the sheath and frame are coaxially mounted and then compressed with initial crimping onto the mounting segment with the tissue leaflet assembly 848 still in a hydrated state.
- the tissue leaflet assembly 848 of the percutaneously deliverable heart valve 860 is then allowed to dry, which further reduces the volume and profile of the tissue membrane leaflets, permitting further compression by radial force. Accordingly, in the final compression step, the percutaneously deliverable heart valve 860 is then further crimped with a circumferential crimping tool at 520 to finally mount the compressed valve/frame onto the delivery mandrel or balloon catheter.
- FIG. 6 the ensheathing, sterilization and packaging at 600 is described. More particularly, once the percutaneously deliverable heart valve 860 is coaxially mounted and crimped on a delivery mandrel or balloon catheter as described above and shown in FIG. 5 , the assembly is then inserted at 604 into a distal end of a delivery sheath, such as by “backloading” the assembly into position with a distal end of the percutaneously deliverable heart valve 860 contained within the delivery sheath proximate the end of the sheath.
- FIG. 10 schematically illustrates catheter 1000 with an implantable prosthetic heart valve 860 mounted thereto.
- the percutaneously deliverable heart valve 860 and delivery catheters are sterilized, such as by using by one or more of ethylene oxide, proton beam, or gamma radiation.
- the assembly is then optionally packaged in a sterile package. Additional elements are optionally shipped with the assembly, wherein, by way of example, such elements may include any necessary delivery tools and documentation.
- the package may optionally contain a device to control the water vapor content within the sealed volume of the package.
- FIG. 13 depicts a surgeon holding a sterile package 1300 containing a premounted percutaneously implantable prosthetic heart valve.
- FIG. 7 a flow chart illustrating the general procedure associated with implantation of the percutaneously deliverable heart valve 860 is provided. More particularly, at 704 , catheter access is gained to the patient's femoral artery and a guidewire is placed through the plane of the diseased valve that is targeted to receive the implant.
- FIG. 14 is a schematic of a simplified cutaway view of a human heart, including heart valves that may be targeted for receiving an embodiment of an implantable prosthetic heart valve.
- FIG. 15 illustrates the aorta with the guidewire placed through the diseased aortic valve.
- the percutaneously deliverable heart valve 860 in the form of a prepackaged assembled dry prosthetic heart valve is removed from the sterile packaging.
- the dry prosthetic heart valve assembly including its lumens, are preferably flushed and prepared in the usual fashion for standard balloons and catheters that do not contain a biocompatible tissue.
- implantation of the dry prosthetic heart valve assembly can be conducted without specific maneuvers for rehydration of the tissue leaflet assembly 848 of the percutaneously deliverable heart valve 860 . Some rehydration of the tissue leaflets may occur as a consequence of the routine flushing of the catheter lumens in preparation for use as with any other catheters.
- implantation of the dry prosthetic heart valve assembly can proceed without additional cleaning steps, such as by having to use alcohol or water rinsing solutions.
- the percutaneously deliverable heart valve 860 can essentially be implanted percutaneously in its dry state.
- the carrier catheter or balloon catheter is then coaxially mounted and advanced over the guidewire, such as under fluoroscopic vision initially to the level of the great vessel where it can be inspected under fluoroscopy.
- the delivery system is advanced through the plane of the diseased valve under fluoroscopy, and the covering sheath is withdrawn, either at this point or during the advance prior to it, thus exposing the mounted implantable prosthetic heart valve 860 in place.
- the balloon is then inflated, deploying the percutaneously deliverable heart valve 860 in the plane of the valve.
- the leaflets of the percutaneously deliverable heart valve 860 operate immediately.
- the deployed prosthetic heart valve 860 is shown in FIG. 16 , wherein the tissue leaflet assembly 848 serves to properly control the flow blood.
- the one or more present inventions include components, methods, processes, systems and/or apparatus substantially as depicted and described herein, including various embodiments, subcombinations, and subsets thereof. Those of skill in the art will understand how to make and use the present invention after understanding the present disclosure.
- the present invention in various embodiments, includes providing devices and processes in the absence of items not depicted and/or described herein or in various embodiments hereof, including in the absence of such items as may have been used in previous devices or processes (e.g., for improving performance, achieving ease and/or reducing cost of implementation).
Abstract
Description
- The present application is a continuation application of U.S. patent application Ser. No. 13/723,541, filed on Dec. 21, 2012, which is a continuation application of U.S. patent application Ser. No. 13/038,361, filed on Mar. 1, 2011, which claims the benefit of U.S. Provisional Patent Application No. 61/309,109 filed on Mar. 1, 2010, the contents of which are incorporated herein by reference in their entireties. Cross-reference is made to U.S. patent application Ser. No. 13/038,260 filed on Mar. 1, 2011, the content of which is incorporated herein by reference.
- The present invention relates to the field of medical devices, and more particularly, to a percutaneously deliverable heart valve and a method of making a percutaneously deliverable heart valve.
- Heart valve disease is a common degenerative condition that compromises physiologic function and causes limiting symptoms and threat to life in millions of patients all over the world. There are various underlying causes, but malfunction of heart valves is ultimately expressed as insufficient conduction of blood through the plane of the valve due to narrowing of the anatomic pathway (stenosis), or as incompetent closure that allows blood to return back through the valve again, thereby reducing the effective forward conduction of blood through the valve (insufficiency or regurgitation). These hemodynamic states lead to 1) deficiency of cardiac output and 2) adverse loads on the pumping chambers of the heart, both of which in turn lead to functional compromise of the patient and often premature death unless effectively corrected.
- Definitive corrective treatment of heart valve disease is conventionally performed by open-chest surgical techniques, wherein the valve is manipulated, repaired, or replaced with a prosthetic valve under direct vision. Heart valve surgery is performed in hundreds of thousands of cases yearly world-wide, but carries a high burden of cost, morbidity, and mortality, especially in susceptible patients who may be elderly or otherwise physiologically compromised by collateral disease. Further, the costs and resource requirements of the surgical enterprise restrict the availability of heart valve replacement to many more patients all over the world.
- In pursuit of alternatives to heart valve surgery, over the last ten years a number of development programs have brought percutaneous, trans-catheter implantation of prosthetic heart valves into commercial use in the European Union (EU) and into pivotal clinical trials in the United States of America. Initial clinical experience in the EU was directed toward patients who had critical aortic valve stenosis, but were deemed to be at unacceptably high risk for open-heart surgical valve replacement. In several thousand such cases, utilizing both balloon-expandable and self-expanding designs in two separate programs, percutaneous heart valve replacement (PHVR) was shown to be feasible and possibly competitive with surgery in selected patients with 12-18 month mortality rates of about 25%. Grube E., et al., Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System, Circ. Cardiovasc Intervent. 2008; 1:167-175.
- The application of PHVR thus far has been challenged by the technical difficulties of the implantation sequence—especially in the aortic valve position. The technique for available devices is limited by the large caliber of the devices and their delivery catheters; often, if it can be done at all in some smaller arteries, open surgical exposure and management of the femoral artery is required to insert the 18-24 French (6-8 mm diameter) systems, and their bulkiness inside the central arteries can threaten the safety of the delivery sequence. Further, access site bleeding complications form a significant part of the adverse events of the procedures.
- Typically, the current PHV designs comprise a biological membrane forming the operating leaflets of the valve, attached within a metal frame, that is then collapsed onto a delivery catheter or balloon, and then constrained within an outer sheath. After an initial dilation of the diseased valve with a large balloon, this assembly is then advanced to the plane of the valve and deployed by self-expansion or by balloon expansion.
- The effective caliber of the valve delivery system is determined by the total bulk of each coaxially mounted component. The bulk of the PHV itself is determined by the diameter of the frame and by the thickness, stiffness, and particular arrangement of the inner membrane forming the operating leaflets of the valve. The characteristic thickness of current PHV membranes is thus a limiting factor in the ultimate delivery profile of the PHV. Such characteristic membrane thickness is, in turn, a result of the methods by which it is processed and ultimately delivered for use. Typically, glutaraldehyde fixation (for protein cross-linking) of animal tissue is employed to produce suitable biological membranes for incorporation. Requirements for strength and durability have determined the most useful ranges for tissue thickness and cross-linking while typically imposing countervailing stiffness and brittleness. Subsequent hydration in suitable solutions improves these characteristics, but the hydrated membrane by this means also gains thickness.
- One of the evident requirements for a PHV design is that the valve functions with a high degree of competence immediately on deployment, since the patient's hemodynamic survival depends on it. To this end, in part, like surgical valve prostheses, current PHV designs are completed, transported, and delivered for use in a hydrated state in a jar of solution. In use, commercially available surgical and percutaneously implanted bioprosthetic heart valves are rinsed and prepared before use in a “wet” state. More particularly, commercially available prosthetic heart valves are rinsed, crimped, and mounted in the catheterization lab. Accordingly, problems with current commercially available prosthetic heart valves include the time, cost and variability associated with the necessity to rinse, crimp, and mount the valve in the catheterization lab. That is, current mounting of prosthetic heart valves in the catheterization lab imposes one or more of delay, cost, technical burdens and possible errors. Avoiding one or more of these problems would be advantageous. In addition, current “wet” valve designs impose additional profile on the collapsed valve. The hydrated membrane, while having desirable and necessary flexibility for reliable operation immediately on deployment, also imposes a large part of the thickness of the assembled and mounted valve that compromises its deliverability.
- Expanding on some of the problems described above, the use of current PHVs in the catheter lab requires a number of preparatory acts that are potentially troublesome and can prolong the delivery sequence during a critical phase of the procedure. Since PHVs are delivered for use “wet” in a preservative solution, they have to be treated prior to insertion with a series of cleansing and hydrating solutions. Once this is completed, the PHVs have to be mounted on their delivery catheters. Special crimping and mounting tools are needed in the case of the balloon-expandable Edwards Sapien valve, for example. Accordingly, there is a need to address the shortcomings discussed above.
- It is to be understood that the present invention includes a variety of different versions or embodiments, and this Summary is not meant to be limiting or all-inclusive. This Summary provides some general descriptions of some of the embodiments, but may also include some more specific descriptions of other embodiments.
- In at least one embodiment, an assembly configured for replacing an aortic or pulmonary heart valve in a human patient is disclosed. The assembly comprises a transcatheter, prosthetic aortic or pulmonary heart valve. The transcatheter, prosthetic aortic or pulmonary heart valve may comprise a frame that is expandable and collapsible, and a tissue leaflet assembly sutured directly to the frame. The tissue leaflet assembly may include three substantially dry leaflets formed from a treated mammalian pericardial tissue that has been treated with glutaraldehyde and glycerol, and that has a thickness of between about 50 to 300 μm. The assembly may further comprise a percutaneously insertable valve delivery mechanism including a including a balloon catheter of size 12 to 14 French, and that includes a guidewire lumen. The transcatheter, prosthetic aortic or pulmonary heart valve may be releasably and coaxially mounted onto the balloon catheter of the percutaneously insertable valve delivery mechanism. The assembly may also include a sterile package containing the transcatheter, prosthetic aortic or pulmonary heart valve that is releasably and coaxially mounted onto the balloon catheter.
- In certain embodiments, the frame may comprise a stent.
- In some embodiments, the treated mammalian pericardial tissue may have an ultimate tensile strength of greater than about 12 MegaPascals.
- In at least one embodiment, the treated mammalian pericardial tissue may not include a matrix that has been exposed to a polymer infiltrate.
- In one or more embodiments, the treated mammalian pericardial tissue may have been treated with distilled water. Additionally and/or alternatively, the treated mammalian pericardial tissue may have been treated with isopropyl alcohol.
- To further clarify the above and other advantages and features of the one or more present inventions, a more particular description of the one or more present inventions is rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the one or more present inventions and are therefore not to be considered limiting of its scope. The one or more present inventions is described and explained with additional specificity and detail through the use of the accompanying drawings in which:
-
FIG. 1 is a flow chart of a method associated with at least of one embodiment of the present invention; -
FIGS. 2A-2B are a flow chart illustrating elements of the tissue preparation; -
FIG. 3 is a flow chart illustrating elements of the drying and sizing; -
FIG. 4 is a flow chart illustrating elements of the valve construction with attachment of tissue membrane leaflets to a frame; -
FIG. 5 is a flow chart illustrating elements of the mounting of the valve into a delivery system; -
FIG. 6 is a flow chart illustrating elements of the ensheathing, sterilization, and packaging; -
FIG. 7 is a flow chart illustrating elements of the delivery of the valve into a patient; -
FIG. 8A is a view of a one-piece section of tissue prior to being folded; -
FIG. 8B is a view of two (of three) separate pieces of tissue after folding (detailed below); -
FIG. 8C is a view of the two pieces of tissue shown inFIG. 8B after being sutured together at the pleat formed after folding (detailed below); -
FIG. 8D is a view of a tissue blank with the line of primary fold shown using a dashed line; -
FIG. 8E is a perspective view of the tissue blank being folded along the primary fold line; -
FIG. 8F is a 2-part figure showing the pleats fold lines and pleats after folding; -
FIG. 8G is a detail perspective view of a single pleat shown inFIG. 8F ; -
FIG. 8H is a perspective schematic view of a folded and seamed tissue leaflet assembly; -
FIG. 8I is a perspective schematic view of a frame; -
FIG. 8J is a perspective schematic view of the frame ofFIG. 8I with the tissue leaflet assembly ofFIG. 8H attached thereto; -
FIG. 8K is side elevation schematic view of the device shown inFIG. 8J ; -
FIG. 8L is an end schematic view of the frame and tissue leaflet assembly attached thereto; -
FIG. 9 is a graph that shows actual stress-strain test results for five tissue samples prepared in accordance with at least one embodiment; -
FIG. 10 is a schematic of a portion of a catheter with a percutaneously deliverable heart valve mounted thereto; -
FIG. 11A is a photo of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a partially open orientation; -
FIG. 11B is a drawing of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation; -
FIG. 11C is a side cutaway view of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation; -
FIG. 11D is another side cutaway view of an implantable prosthetic heart valve, including a tissue leaflet assembly attached within a frame, wherein the tissue is situated in a closed orientation; -
FIG. 12 is a photo of valve tissue after testing through 30,000,000 cycles of pumping used to model human heart conditions, wherein the photo shows a smooth uniform surface; -
FIG. 13 is a drawing of a surgeon holding a premounted percutaneously deliverable heart valve associated with a catheter and residing within sterile packaging; -
FIG. 14 is a schematic of a simplified cutaway view of a human heart, including heart valves that may be targeted for receiving an embodiment of an implantable prosthetic heart valve; -
FIG. 15 is a schematic of a human aorta receiving a catheter with an implantable prosthetic heart valve mounted thereto; -
FIG. 16 is a schematic of a human aorta with the implanted prosthetic heart valve implanted at the site of the original diseased aortic valve; and -
FIG. 17 is a schematic of a prosthetic heart valve and a mandrel of a delivery catheter. - The drawings are not necessarily to scale.
- Embodiments of the one or more inventions described herein include one or more devices, assemblies and/or methods related to a prosthetic heart valve. A prosthetic heart valve in accordance with at least one embodiment described herein can be surgically implanted, such as by percutaneous, trans-catheter delivery, to the implantation site within the patient. One or more embodiments of the prosthetic heart valves described herein have application for at least aortic and pulmonary valve positions, including for structural defects and diseased valves.
- In at least one embodiment, biocompatible material is attached within a frame to form an implantable prosthetic heart valve, and then at a later time, the implantable prosthetic heart valve is implanted within a patient, such as by way of a percutaneous, trans-catheter delivery mechanism. Once implanted, the prosthetic heart valve serves to regulate the flow of blood associated with the patient's heart by allowing forward blood flow and substantially preventing backflow or valvular regurgitation.
- Referring now to
FIG. 1 , a flow chart illustrates at least one embodiment of a prosthetic heart valve preparation anddelivery method 100. The prosthetic heart valve preparation anddelivery method 100 generally includes a plurality of procedures to include tissue preparation at 200, drying at 300, tissue leaflet assembly construction and attachment to frame at 400 to form an implantable prosthetic heart valve, mounting of the prosthetic heart valve (that is, the frame with the tissue leaflet assembly) into a delivery system at 500, ensheathing, sterilizing and packaging the delivery system including the prosthetic heart valve at 600, and finally, delivering the prosthetic heart valve into the patient at 700. Further detail of the prosthetic heart valve preparation anddelivery method 100 is provided below. - At least one or more embodiments described herein include a relatively thin tissue component. By way of example and not limitation, in at least one embodiment the tissue has a thickness of approximately 50-150 μm, and further possesses characteristics of pliability and resistance to calcification after implantation. The relatively thin nature of the tissue used in the implantable prosthetic heart valve assists with biocompatibility. In addition, the relatively thin tissue component thereby provides for a relatively low mass. As a result, an implantable prosthetic heart valve using the tissue can accelerate to a relatively high heart rate in beats per minute with competent function.
- Tissue suitable for use in the one or more prosthetic heart valves and/or one or more assemblies described herein is relatively thin and can generally be considered to be a membrane. Those skilled in the art will appreciate that both natural and synthetic types of materials may be used to form a leaflet assembly of a prosthetic heart valves. Accordingly, it is to be understood that although treated pericardium tissue is described as a suitable material for use in the leaflet assembly of a prosthetic heart valve of one or more embodiments described herein, material other than xenograft tissue membrane can be used, and indeed, xenograft tissue membrane other than pericardium tissue can be used. More specifically, synthetic materials may include, but are not limited to, PTFE, PET, Dacron, and nylon. In addition, other than pericardium tissue, xenograft tissue membrane may include, but is not limited to, membrane material from the intestine, lung and brain. Suitable material may also comprise allograft material, that is, material from human sources. The listing of possible materials is for exemplary purposes and shall not be considered limiting.
- With reference now to
FIG. 2A , the process associated with preparation of a biocompatible tissue consistent with the above-noted characteristics is described. In at least one embodiment, pericardium tissue, such as porcine or bovine pericardium tissue, is harvested at 204 and then processed to serve as the biocompatible tissue for association with a frame, such as by attaching within a frame. Accordingly, subsequent to the harvesting at 204, the pericardium tissue is cleaned and decellularized at 208. More particularly, in at least one embodiment the tissue is initially cleaned with distilled water using gentle rubbing and hydrodynamic pressure at 208 in order to remove adherent non-pericardial and non-collagenous tissue. In at least one embodiment, the hydrodynamic pressure at 208 is provided by spraying the tissue with a relatively weak stream of liquid to remove at least some of the non-collagenous material associated with the tissue. The rinsing at 208 is to achieve effective decellularization of the pericardium tissue through osmotic shock. Typically, the thickness of the tissue in the cleaned condition varies from about 50 to 500 micrometers, depending on the source of raw tissue. Cleaning preferably continues until there is no visible adherent non-pericardial or non-collagenous tissue. - With continued reference to
FIG. 2A , after the tissue has been cleaned and decellularized at 208, the tissue then undergoes optional additional removal of lipids at 220 to further treat the tissue for preventing immunologic response and calcification. More particularly, the tissue first optionally undergoes a 100% glycerol pretreatment at 224 while being positioned on a flat surface (e.g., an acrylic plate), after which the tissue becomes nearly transparent. - At 228, the tissue optionally undergoes a “thermophotonic” process. In at least one embodiment, the tissue is optionally exposed to light energy for additional removal of lipids and for initial cross-linking of the collagen. By way of example and not limitation, in at least one embodiment a 25-100 watt incandescent light source, and more preferably, a 50 watt incandescent light source with a flat radiant face is employed at a distance of about 10 centimeters from the tissue surface, typically requiring 15 minutes of exposure before further visible separation of lipid droplets from the tissue stops.
- Still referring to
FIG. 2A , the tissue is then cleaned again in secondary cleaning at 232. More particularly, at 236 the tissue is again rinsed with distilled water. Thereafter, at 240 the tissue is rinsed with 25% isopropyl alcohol for periods of several hours to several days and weeks, depending on the desired tissue properties of pliability and tensile strength. By way of example and not limitation, tissue has been successfully prepared by rinsing with 25% isopropyl alcohol for a period of 7 days, and after further treatment steps described herein, provided an ultimate tensile strength of greater than 25 MegaPascals. Here, the combination of tissue pliability and tensile strength is sought for purposes of producing a material having property characteristics suitable for being physically manipulated to form a tissue leaflet assembly or other configuration appropriate for attaching with a frame, while providing a tissue material that will operate properly once implanted. These techniques are intended to conserve and preserve collagen fibers, minimizing damage to the tissue and improving tissue characteristics. The preparation and fixation techniques produce tissue membrane material that may be rendered and used at lesser thickness than typically rendered in the prior art. Thinner membranes are more pliable, but with conventional preparation techniques the tensile strength of the tissue is sacrificed. Advantageously, the preparation techniques described herein have produced membranes that have as much as three times the tensile strength of a commercial product of the prior art. This achieved strength is thus enabling for providing a tissue leaflet assembly having a low profile with appropriate durability, even in a substantially dry state. More particularly, the tissue possesses a relatively high tensile strength. By way of example and not limitation, testing has shown that embodiments of tissue prepared as described herein provide a tissue with a tensile strength of approximately three times the tensile strength of current pericardial valve tissue, such as on the order of approximately 25 MegaPascals, thereby providing about 2000 times the physiologic load strength for valve tissue. Moreover, testing of an embodiment of an implantable prosthetic heart valve made with tissue prepared as described herein and under a static load of greater than approximately 250 mmHg showed less than approximately 14% leakage, wherein such results are generally considered superior to surgical tissue valve prostheses. - In at least one embodiment where isopropyl alcohol is described as a rinsing agent, ethanol may be used in its place as an alternative, although resulting tissue properties may vary.
- With reference to
FIG. 9 , stress-strain curve results for five different tissue samples prepared in accordance with an embodiment are shown. For the testing results shown, the yield stress or ultimate tensile strength was obtained by mounting strips of tissue fixed at the ends in a linear force tester and increasing the length by 0.3 mm/sec while recording resultant force (tension) until the material ruptured or separated entirely; these measurements were then used to calculate the stress-strain curves depicted inFIG. 9 . As illustrated in the graph, the yield stress or ultimate tensile strength of the various tissue samples varied from about 30 to about 50 MegaPascals. More particularly, for each curve shown inFIG. 9 , the testing procedures were the same. That is, each of the curves shown pertain to separate pieces of tissue that were subjected to the same test. The results show a minimum ultimate tensile strength of 30 MegaPascals, with a range up to 50 MegaPascals. Accordingly, the illustrated test results demonstrate consistency of the ultimate tensile strength results for the tissue treatment process. - With reference back to
FIG. 2A , the tissue is rinsed with distilled water at 244 as a final cleaning step and for rehydration. - Referring now to
FIG. 2B , following the rinse with distilled water at 244, treatment of the tissue continues. More particularly, fixation for collagen cross-linking at 248 is achieved by performing at least one of the following: -
- a. At 248 a, immersion of the tissue in 1-37.5% formalin, ideally a buffered solution, for between about 3 days to 5 weeks, and more preferably, for between about 3 days to 4 weeks, and more preferably yet, for between about 3 weeks to 4 weeks, at a temperature of between about 4 to 37° C., and more preferably, 10% formalin for 6 days at 20° C.; or
- b. At 248 b, immersion of the tissue in 100% glycerol for up to 6 weeks at between 4 to 37° C., and more preferably, immersion of the tissue in 100% glycerol for about 3 weeks at 20° C.; or
- c. At 248 c, immersion of the tissue in 0.1-25% glutaraldehyde for between about 3 days to 5 weeks, and more preferably, for between about 3 days to 4 weeks, and more preferably yet, for between about 3 weeks to 4 weeks, at 0 to 37° C., and more preferably, immersion of the tissue in 0.25% glutaraldehyde for 7 days at 4° C.; or
- d. At 248 d, immersion of the tissue in 0.1-25% glutaraldehyde (filtered to limit oligomeric content) for between about 3 days to 5 weeks, and more preferably, for between about 3 days to 4 weeks, and more preferably yet, for between about 3 weeks to 4 weeks, at 0 to 37° C., and more preferably, 0.25% glutaraldehyde for 7 days at 4° C.; or
- e. At 248 e, immersion in the tissue in one of the above formalin, glutaraldehyde, or oligomeric filtered glutaraldehyde solutions together with added amino acids, lysine and/or histidine, wherein the concentration of the amino acids, L-lysine or histidine, used as an additive to the fixative is in the range of about 100-1000 milliMolar, with a preferred value of about 684 mM.
- In addition to the foregoing, combinations of the processes listed above may be performed, including: step a followed by step b; step a followed by step c; and step a followed by step d.
- As those skilled in the art will appreciate, heat-shrink testing may be conducted on tissue samples to correlate the effectiveness of protein cross-linking. Here, results of heat-shrink testing performed on one or more samples of tissue prepared in accordance with at least one embodiment using formalin showed that the tissue had a shrink temperature of 90° C. This compares favorably with samples prepared using glutaraldehyde, wherein the shrink temperature was 80° C. Accordingly, formalin is a suitable variant of fixation. It is noted that formalin was generally abandoned by the field, largely because of material properties that were unfavorable and because of inadequate or unstable protein cross-linking. Such problems have been overcome through the pretreatments described herein, allowing production of tissue with strength, pliability, and durability in a relatively thin membrane. When used in a percutaneous deliverable heart valve (also referred to herein as “prosthetic heart valve”), the tissue characteristics imparted by the tissue preparation process facilitate formation of a construct having a relatively low-profile, which also thereby facilitates dry packaging of the prosthetic heart valve. The same advantages are also achieved using the pretreatments when using a glutaraldehyde process.
- Referring still to
FIG. 2B , after fixation for collagen cross-linking at 248, an alcohol post-fixation treatment at 252 is preferably performed by rinsing the tissue in distilled water at 256, and then at 260 rinsing the tissue in 25% isopropyl alcohol for between about 30 minutes to 14 days or more at between about 0 to 37° C., and more preferably, for at least about 7 days at 20° C. At 264, the tissue undergoes a rinsing with distilled water. - In accordance with at least one embodiment, treatment of the tissue, including from the time of harvest to the time of implantation or grafting, does not include contact and/or exposure to a polymer to infiltrate and/or encapsulate tissue fibers of the tissue.
- Referring now to
FIGS. 1 and 3 , the drying process at 300 is performed after the tissue preparation at 200. Thus, in accordance with at least one embodiment, the tissue is dried under a load. More particularly, for the tissue drying at 304, the tissue is placed minimally stretched flat (that is, stretched just enough to eliminate visible wrinkles and bubbles) on a flat surface (e.g., a polymer or acrylic sheet) at 308, and held fixed at its edges at 312. Optionally, the joined tissue and underlying sheet are then set in a slight curve. The tension maintains the substantially flat structure of the tissue as it dries, thereby mitigating or preventing excessive shrinkage, wrinkling, and/or curling at the edges, and also making the rate of drying more uniform across the surface of the tissue because of the surface tension between the plate and the tissue. Alternatively, the tissue is dried while compressed between acrylic plates. When drying the tissue, the temperature is held at between about 4 to 37° C., and more preferably, between about 20 to 37° C. (i.e., approximately room temperature to normal human body temperature), and more preferably, at about 20° C. At 314, the drying process is performed in substantially dark conditions (i.e., substantially no visible light) for between about 6 hours to 5 days, and more preferably, for about 72 hours. By way of example, the tissue is dried in dark conditions at a temperature of about 20° C. for between about 6 hours to 5 days, and more preferably, for about 72 hours. As those skilled in the art will appreciate, drying the tissue while the tissue is compressed between plates requires a longer period of time. - In at least one embodiment, after drying, the tissue lots are inspected at 316, such as by stereomicroscopy, to identify and discard those with defects or discontinuities of the fiber matrix. In addition, the preferential fiber direction for each piece is identified to determine the necessary orientation of the free edge of the pieces that will form the valve leaflets. Depending upon the size (i.e., the area) of the tissue being prepared and the size of tissue needed for a given valve, the tissue may be trimmed or otherwise sized in optional sizing at 320, such as by cutting the tissue into an appropriately sized and shaped sheet for valve formation. Preferably, cutting of the tissue membrane is oriented so that the resulting free edge of the leaflet is parallel to the preferential fiber direction of the tissue membrane. Optionally, the free edge of the leaflets may also be cut with a parabolic or other curved profile to compensate for the downward angle from the commissural leaflet attachment point to the central coaptation point and to increase the total contact surface between the coapting leaflets. This approach minimizes focal weaknesses in the operating margins of the leaflet assembly and advantageously distributes the principal loading forces of the operating valve along the long axis of the collagen fibers. As a result, the tissue is resistant to surface fracture and fraying. As shown in
FIG. 3 , optional sizing at 320 is performed after the drying at 304 and inspection at 316. - With reference now to
FIG. 4 , an embodiment associated with forming a tissue leaflet assembly and attachment to a frame to form a prosthetic heart valve at 400 is further described. It is to be understood that the tissue generated from one or more of the tissue preparation procedures described herein may be used for a variety of devices or uses, and that use in a prosthetic heart valve is but one possible application for utilizing the tissue. For example, the tissue may be used in a shunt, or as graft material for repair or modification of one or more human organs, including the heart and its blood vessels. By way of further example, the tissue may be used as a pericardial membrane patch for repair of congenital heart defects. The tissue also has application as a prosthetic tissue in tendon and ligament replacement, and as a tissue product for wound management. Moreover, for use in a prosthetic heart valve, the tissue may be configured in a variety of ways and attached to a frame in a variety of ways. By way of example and not limitation, in at least one embodiment, the prepared tissue is formed into a tissue leaflet assembly at 404 by folding the tissue at 408, preferably while the tissue is in a dry state, to form at least a portion of the tissue leaflet assembly. Here, those skilled in the art will appreciate that a completed tissue leaflet assembly may be formed of a single monolithic piece oftissue 800, such as that shown inFIG. 8A , or alternatively, as shown inFIGS. 8B and 8C , it may be formed of a plurality oftissue pieces 802 that are operatively connected, such as by gluing or sewing the tissue pieces together alongseams 804. As seen inFIG. 8C , theseams 804 are preferably situated at overlapping portions ofpleats 832 of the plurality oftissue pieces 802. - As those skilled in the art will further appreciate, a single monolithic piece of
tissue 800 or a plurality oftissue pieces 802 may be used to form a prosthetic heart valve, wherein the tissue leaflet assembly is not a folded construct. By way of example and not limitation, a plurality of separate tissue pieces may each be attached to a frame (such as by suturing) to form a prosthetic heart valve. Thereafter, whether the prosthetic heart valve is made of a folded tissue leaflet assembly or a plurality of separate tissue pieces attached to a frame, the resulting prosthetic heart valve may then be further manipulated for delivery as a dry prosthetic heart valve. - In an alternative embodiment, tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that includes a frame, and that may be implanted by a “trans-apical” approach in which the prosthetic heart valve is surgically inserted through the chest wall and the apex of the heart.
- In yet another alternative embodiment, tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that does not include a frame, and is not delivered via a catheter, but rather, is implanted via a surgical opening through the patient's chest. In such a case, the prosthetic heart valve may be packaged for delivery as a dry prosthetic heart valve.
- In still yet another alternative embodiment, tissue generated from one or more of the tissue preparation procedures described herein may be used to form a prosthetic heart valve that includes a frame, but that is not delivered via a catheter, but rather, is implanted via a surgical opening through the patient's chest. In such a case, the prosthetic heart valve may be packaged for delivery as a dry prosthetic heart valve.
- As a further alternative to the embodiments described herein, tissue may be implanted in a “wet” or hydrated state. For example, a prosthetic heart valve utilizing a prepared tissue described herein may be packaged for delivery as a hydrated prosthetic heart valve. Accordingly, while a portion of the tissue preparation process may include drying the tissue so that it may be manipulated more easily, the tissue may then be hydrated at a later point in time prior to implantation, and it may be maintained in a hydrated condition up to and including packaging, delivery and implantation into a patient. Advantages associated with using a folded tissue leaflet assembly include that a folded structure allows a relatively thin membrane to be used by avoiding suture lines in loaded, dynamically active surfaces. Accordingly, a sutureless leaflet assembly preserves long-term integrity. However, it is to be understood that a prosthetic heart valve that does not include a folded tissue leaflet assembly is encompassed by one or more embodiments described herein.
- With reference now to
FIGS. 8D-8L , and in accordance with at least one embodiment, for a prosthetic heart valve that includes a tissue leaflet assembly formed of a folded tissue membrane, the folding sequence for the tissue is shown for configuring the tissue into a completed tissue leaflet assembly. More particularly, a tissue blank 808 is shown inFIG. 8D , wherein the tissue blank 808 is a single monolithic piece oftissue 800. Depending upon the size requirements for a given tissue leaflet assembly, a line of primary fold or fold line 812 (shown as a dashed line) is visualized for thetissue blank 808. As shown inFIG. 8D , theprimary fold 814 is achieved along thefold line 812 by folding thebottom edge 816 of the tissue blank 808 toward thetop edge 820, but leaving acuff portion 824 along theupper portion 828 of thetissue blank 808. Here, it is noted that the direction of top and bottom are relative to each other and are used as a convenience for describing the folding sequence, wherein such directions correspond to the orientation of the page illustrating the drawings. Advantageously, the folding geometry ofFIGS. 8D-8L forms cuffs 824 that are continuous with the leaflets, thereby reducing the risk of aortic insufficiency or leakage. - With reference now to
FIG. 8F , after folding the tissue blank 808 alongfold line 812 to formprimary fold 814, pleats are formed by folding the tissue along its length. For the embodiment shown inFIG. 8F , threepleats FIG. 8G illustrates a detail drawing of asingle pleat 832 representative of one ofpleats 832 a-c. InFIG. 8G , the inner leaflet layerfree edge 836 is shown, as is thevalve sinus 840 and the commissure folds 844. - Referring again to
FIG. 4 as well asFIG. 8H , at 412 the folded tissue is seamed to form a folded tissue leaflet assembly. More particularly,FIG. 8H shows a schematic perspective drawing oftissue leaflet assembly 848, wherein the pleated tissue construct shown in the bottom half ofFIG. 8F is seamed, such as alongseam 850, to form a substantially tubular construct. At 416, the foldedtissue leaflet assembly 848 is maintained dry or is partially hydrated prior to mounting the tissue leaflet assembly in a frame. At 420, thetissue leaflet assembly 848 is then attached within a frame, such asframe 852 shown inFIG. 8I . Thetissue leaflet assembly 848 attached within aframe 852 forms an implantableprosthetic heart valve 860, such as that shown in the schematic perspective drawing ofFIG. 8J , side elevation viewFIG. 8K , as well as that shown in the photo ofFIG. 11A , and drawing ofFIG. 11B .FIG. 8K illustrates possible suture points 864 where thetissue leaflet assembly 848 can be sutured to theframe 852. That is, thetissue leaflet assembly 848 may be attached within theframe 852, such as by suturing the outer layer of thetissue leaflet assembly 848 to the frame. In the foregoing sentence, and as used herein, it is noted that the term “attached” means that thetissue leaflet assembly 848 is secured to theframe 852, although the inner leaflet layerfree edges 836 are able to readily move during operation of theprosthetic heart valve 860. - Referring now to
FIG. 11C , a cutaway side elevation view of aprosthetic heart valve 860 that includes aframe 852 with atissue leaflet assembly 848 attached therein is shown. The tissuemembrane leaflet assembly 848 is disposed coaxially within theframe 852. As shown inFIG. 11C , thevalve 860 is illustrated in the closed position with the leafletfree edges 836 in at least partial contact with each other. Anarc 1112 of the leaflet free edges 836 (out of plane of the cutaway view) is continuous withpleats 832 at the radial edge of thetissue leaflet assembly 848, and may be seen in the alternate view shown inFIG. 8L . The tissuemembrane leaflet assembly 848 is attached to theframe 852 along the axially oriented membrane pleats 832, as illustrated again inFIG. 8L . The extended cuff layer is attached circumferentially at thedistal edge 1104 of theframe 852. By way of example and not limitation,continuous suture attachment 1108 may be used to attach the extended cuff layer to thedistal edge 1104. - Referring now to
FIG. 11D , an embodiment is shown wherein the cuff layer is not extended distally to thedistal edge 1104 of theframe 852. As shown inFIG. 11D , the distal edge of the cuff layer is attached circumferentially to an inner aspect of theframe 852, such as along those possible suture points 864 illustrated inFIG. 8K . As a result, adistal portion 1116 of theframe 852 does not include any portion of thetissue leaflet assembly 848, such as the cuff layer. However, with thevalve 860 in the closed position the leafletfree edges 836 still at least partially contact each other. - With reference now to
FIG. 8L , an end view of the prosthetic heart valve is shown. As depicted inFIG. 8L , thepleats 832 are used as the portion of thetissue leaflet assembly 848 to attach to theframe 852. As can be seen inFIG. 8L , the outer cuff layer is attached to the frame members offrame 852. When theprosthetic heart valve 860 is closed, thecusps 868 formed by the inner leaflet layer are generally situated as depicted inFIG. 8L .FIG. 12 is a photo of the tissue leaflets of a prosthetic heart valve after 30,000,000 cycles of testing to model performance if associated with a human heart. In testing, theprosthetic heart valve 860 has demonstrated a natural opening gradient of approximately 5 mmHg. - It will be appreciated by one of ordinary skill in the art that the
tissue leaflet assembly 848 described and shown herein is but one possible construct for forming a flow control mechanism that can be attached to a frame to regulate the flow of blood in a patient's vascular system upon deployment. That is, the illustratedtissue leaflet assembly 848 is provided by way of example and not limitation, and in no way should be interpreted to limit the geometries of membrane leaflet assemblies that can be used to regulate fluid flow. Accordingly, other leaflet configurations and constructs are considered encompassed by claims directed to or otherwise including premounted percutaneously deliverable valves. - As those skilled in the art will appreciate, the
frame 852 may be a stent or a structure having similarities to a stent. Theframe 852 essentially serves as a holding mechanism for thetissue leaflet assembly 848 that can then be inserted percutaneously into a patient, wherein theframe 852 serves as a way to anchor the foldedtissue leaflet assembly 848 to a vascular portion (e.g., in situ arterial tissue) of the patient. Thus, at 424 thetissue leaflet assembly 848 is inserted into aframe 852. More particularly, at 424 a theframe 852 may comprise a balloon-expandable frame, or alternatively, at 424 b a self-expanding frame may be used. After the tissue leaflet assembly is inserted into the frame, at 428 the foldedtissue leaflet assembly 848 is attached to theframe 852, such as by suturing thetissue leaflet assembly 848 to theframe 852 to form an implantableprosthetic heart valve 860, such as that shown inFIG. 8L . In at least one embodiment, after attaching thetissue leaflet assembly 848 within theframe 852 and connecting thetissue leaflet assembly 848 to theframe 852 to form an implantableprosthetic heart valve 860, at 432 theprosthetic heart valve 860 is fully hydrated for inspection and testing. Thereafter, the fully constructed implantableprosthetic heart valve 860 may be dried and maintained in a substantially dry condition. Accordingly, as those skilled in the art will appreciate, one or more embodiments described herein provide atissue 800 suitable for implanting in a human, wherein the implantable tissue may be allowed to dry prior to implanting, or it may be hydrated prior to implanting. In addition, thetissue 800 is suitable for use in forming atissue leaflet assembly 848 for use in a prosthetic heart valve, including an implantableprosthetic heart valve 860 that can be implanted with its tissue leaflet assembly in a dry state, or with its tissue leaflet assembly in a partially or fully hydrated state. - One or more of the embodiments of the tissue leaflet assemblies described herein may be implanted into the patient using a balloon-expandable frame or a self-expanding frame. Expandable frames are generally conveyed to the site of the target valve on balloon catheters. For insertion, the expandable frame is positioned in a compressed configuration along the delivery device, for example crimped onto the balloon of a balloon catheter that is part of the delivery device intended for coaxial mounting on a guidewire. After the expandable frame is positioned across the plane of the valve, the expandable frame is expanded by the delivery device. For a self-expanding frame, commonly a sheath is retracted, allowing expansion of the self-expanding frame.
- In at least one embodiment, the frame comprises a metal alloy frame possessing a high strain design tolerance that is compressible to a relatively small diameter. By providing a device with a low profile, the implantable
prosthetic heart valve 860 allows standard retrograde arterial aortic delivery via femoral artery insertion, without surgical cutdown or general anesthesia. This is achieved by providing the prosthetic heart valve on a premounted delivery system with the tissue leaflet assembly or tissue membrane construct in a substantially dry condition. - In accordance with one or more embodiments, a dry tissue membrane has substantially less mass than a wet membrane. By way of example, a substantially dry pericardium tissue prepared by one or more of the present embodiments has approximately 30% of the mass of a wet pericardium tissue, and marked reduction in profile and packing volume, thereby achieving a relatively low profile and making it suitable for implantation in greater number of patients, especially those having small diameter vascular systems. In addition, a dry prosthetic heart valve does not require storage and transport in preservative. A dry prosthetic heart valve can be mounted on a delivery catheter at its location of manufacture, which allows for pre-packaging of an integrated delivery system. In the foregoing sentence, it is noted that the term “mounted” means that the
prosthetic heart valve 860 is temporarily associated with the delivery catheter. Together with a relatively low profile, embodiments of the prosthetic heart valve thereby offer reliability and convenience because the implantableprosthetic heart valve 860 is pre-mounted upon its delivery catheter and forms part of a pre-packaged delivery system. In addition, a dry prosthetic heart valve does not require rinsing, rehydration, or mounting in a catheterization lab. Therefore, a dry prosthetic heart valve can be inserted directly from package into the patient's body at a critical time during the procedure. Advantageously, this avoids procedure time, manipulation, and errors of mounting, crimping, and orienting catheters and sheaths. Once at the surgical facility/location, the dry prosthetic heart valve is inserted and delivered by balloon catheter expansion in the plane of the target valve in the standard way and the dry prosthetic heart valve begins to function immediately, even without specific steps to rehydrate the tissue membrane portion of the heart valve from its dry state, with hydration of the tissue membrane subsequently occurring rapidly and naturally in the body. More particularly, hydration of the tissue membrane portion occurs rapidly and begins with simple preparatory flushing of catheter lumens with saline. Thereafter, hydration continues with device insertion and dwelling into the central blood vessels, and completes naturally after deployment in the patient's body. - The low profile of the implantable prosthetic valve is particularly advantageous for patient's having relatively small diameter vascular systems. Table 1 provides aortic and pulmonary valve prosthesis sizing.
-
TABLE Aortic and Pulmonary Valve Prosthesis Sizing Collapsed Implantable Collapsed Implantable Aorta/Pulmonary Valve Prosthetic Heart Valve Prosthetic Heart Valve Diameter Size (French) Diameter 19-21 mm 12 French 4.0 mm 22-26 mm 14 French 4.7 mm 27-30 mm 16 French 5.3 mm - For most human patients, the femoral artery has a diameter of between about 5-8 mm. Accordingly, it is apparent that embodiments of the collapsed implantable
prosthetic heart valves 860 described herein offer a low profile that enables a larger group of patients to qualify for receiving an implantableprosthetic heart valve 860. As a result of the sizing advantages offered by one or more embodiments of implantableprosthetic heart valves 860 described herein, virtually no candidate patients would be excluded from treatment with an implantableprosthetic heart valve 860 without open heart surgery and without general anesthesia on the basis of inadequate femoral blood vessel access caliber. In addition, one or more embodiments of the implantableprosthetic heart valve 860 described herein feature a scalable construct, wherein the implantableprosthetic heart valves 860 can be produced to accommodate target valve diameters ranging between 6-35 mm, and wherein the implantableprosthetic heart valves 860 offer consistent function using fundamentally a single design. - Referring now to
FIG. 5 , the mounting of the implantableprosthetic heart valve 860 into a delivery system at 500 is further described. More particularly, at 504 an implantable prosthetic heart valve 860 (also referred to herein as a percutaneously deliverable heart valve) is collapsed. The initial phase of collapsing the percutaneously deliverable heart valve is executed with the tissue membrane in a hydrated condition. That is, since the percutaneouslydeliverable heart valve 860 includes theframe 852 with thetissue leaflet assembly 848 attached within theframe 852, the percutaneouslydeliverable heart valve 860 is collapsed down as an integral unit. If a balloon-expandable frame is used, then an axial puller may be utilized to collapse down theframe 852 of the percutaneouslydeliverable heart valve 860 without the application of force directly to the sides of theframe 852. This procedure offers the advantage of preserving the cell structure of theframe 852 while also maintaining the orientation of the leaflets of thetissue leaflet assembly 848 as the percutaneouslydeliverable heart valve 860 is compressed. The proper orientation and disposition of the leaflets is facilitated by the hydrated state of the leaflets. This assists in preventing tissue prolapse or bulging of thetissue frame 852. In addition, this technique reduces recompression strain on the metal frame 852 (e.g., a stent) that can tend to compromise fatigue life of theframe 852. This technique also tends to promote the circumferentially uniform collapsing of cells in theframe 852, thereby mitigating bunching of the tissue that forms thetissue leaflet assembly 848 of the percutaneouslydeliverable heart valve 860. For a self-expanding frame, the sides are forced to collapse by providing a radial compression force to the frame and may be assisted by axial traction force. - With further reference to
FIG. 5 , the percutaneously deliverable heart valve 860 (i.e., theframe 852 with thetissue leaflet assembly 848 attached thereto) is collapsed in an initially hydrated state. At 508 the delivery mandrel 1704 (as best seen inFIG. 17 ) or balloon is inserted into a delivery sheath, and the mounting segment is then extended out the end of the sheath. Thereafter, at 512 the sheath and frame are coaxially mounted and then compressed with initial crimping onto the mounting segment with thetissue leaflet assembly 848 still in a hydrated state. At 516, thetissue leaflet assembly 848 of the percutaneouslydeliverable heart valve 860 is then allowed to dry, which further reduces the volume and profile of the tissue membrane leaflets, permitting further compression by radial force. Accordingly, in the final compression step, the percutaneouslydeliverable heart valve 860 is then further crimped with a circumferential crimping tool at 520 to finally mount the compressed valve/frame onto the delivery mandrel or balloon catheter. - Referring now to
FIG. 6 , the ensheathing, sterilization and packaging at 600 is described. More particularly, once the percutaneouslydeliverable heart valve 860 is coaxially mounted and crimped on a delivery mandrel or balloon catheter as described above and shown inFIG. 5 , the assembly is then inserted at 604 into a distal end of a delivery sheath, such as by “backloading” the assembly into position with a distal end of the percutaneouslydeliverable heart valve 860 contained within the delivery sheath proximate the end of the sheath. Reference here is made toFIG. 10 that schematically illustratescatheter 1000 with an implantableprosthetic heart valve 860 mounted thereto. - With further reference to
FIG. 6 , at 608 the percutaneouslydeliverable heart valve 860 and delivery catheters are sterilized, such as by using by one or more of ethylene oxide, proton beam, or gamma radiation. At 612, the assembly is then optionally packaged in a sterile package. Additional elements are optionally shipped with the assembly, wherein, by way of example, such elements may include any necessary delivery tools and documentation. In at least one embodiment, the package may optionally contain a device to control the water vapor content within the sealed volume of the package.FIG. 13 depicts a surgeon holding asterile package 1300 containing a premounted percutaneously implantable prosthetic heart valve. - Referring now to
FIG. 7 , a flow chart illustrating the general procedure associated with implantation of the percutaneouslydeliverable heart valve 860 is provided. More particularly, at 704, catheter access is gained to the patient's femoral artery and a guidewire is placed through the plane of the diseased valve that is targeted to receive the implant.FIG. 14 is a schematic of a simplified cutaway view of a human heart, including heart valves that may be targeted for receiving an embodiment of an implantable prosthetic heart valve.FIG. 15 illustrates the aorta with the guidewire placed through the diseased aortic valve. At 708, the percutaneouslydeliverable heart valve 860 in the form of a prepackaged assembled dry prosthetic heart valve is removed from the sterile packaging. The dry prosthetic heart valve assembly, including its lumens, are preferably flushed and prepared in the usual fashion for standard balloons and catheters that do not contain a biocompatible tissue. Advantageously, implantation of the dry prosthetic heart valve assembly can be conducted without specific maneuvers for rehydration of thetissue leaflet assembly 848 of the percutaneouslydeliverable heart valve 860. Some rehydration of the tissue leaflets may occur as a consequence of the routine flushing of the catheter lumens in preparation for use as with any other catheters. Additionally, implantation of the dry prosthetic heart valve assembly can proceed without additional cleaning steps, such as by having to use alcohol or water rinsing solutions. In addition, further mounting of the drytissue leaflet assembly 848 that resides in theframe 852 of the percutaneouslydeliverable heart valve 860 is not needed, thereby obviating the need for another mounting step. Accordingly, the percutaneouslydeliverable heart valve 860 can essentially be implanted percutaneously in its dry state. At 712, the carrier catheter or balloon catheter is then coaxially mounted and advanced over the guidewire, such as under fluoroscopic vision initially to the level of the great vessel where it can be inspected under fluoroscopy. At 716, and after the nominal position and configuration is confirmed, the delivery system is advanced through the plane of the diseased valve under fluoroscopy, and the covering sheath is withdrawn, either at this point or during the advance prior to it, thus exposing the mounted implantableprosthetic heart valve 860 in place. At 720, in the case of a balloon expandable frame, and assuming the delivery approach involving the pre-mounting of the percutaneouslydeliverable heart valve 860 on the expansion balloon, the balloon is then inflated, deploying the percutaneouslydeliverable heart valve 860 in the plane of the valve. At 724, the leaflets of the percutaneouslydeliverable heart valve 860 operate immediately. The deployedprosthetic heart valve 860 is shown inFIG. 16 , wherein thetissue leaflet assembly 848 serves to properly control the flow blood. - The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
- The one or more present inventions, in various embodiments, include components, methods, processes, systems and/or apparatus substantially as depicted and described herein, including various embodiments, subcombinations, and subsets thereof. Those of skill in the art will understand how to make and use the present invention after understanding the present disclosure.
- The present invention, in various embodiments, includes providing devices and processes in the absence of items not depicted and/or described herein or in various embodiments hereof, including in the absence of such items as may have been used in previous devices or processes (e.g., for improving performance, achieving ease and/or reducing cost of implementation).
- The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the invention are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate preferred embodiment of the invention.
- Moreover, though the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention (e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure). It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or acts to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or acts are disclosed herein, and without intending to publicly dedicate any patentable subject matter.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/265,573 US20190159897A1 (en) | 2010-03-01 | 2019-02-01 | Percutaneously Deliverable Heart Valve and Methods Associated Therewith |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30910910P | 2010-03-01 | 2010-03-01 | |
US13/038,361 US8361144B2 (en) | 2010-03-01 | 2011-03-01 | Percutaneously deliverable heart valve and methods associated therewith |
US13/723,541 US20130123914A1 (en) | 2010-03-01 | 2012-12-21 | Percutaneously deliverable heart valve and methods associated therewith |
US16/265,573 US20190159897A1 (en) | 2010-03-01 | 2019-02-01 | Percutaneously Deliverable Heart Valve and Methods Associated Therewith |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/723,541 Continuation US20130123914A1 (en) | 2010-03-01 | 2012-12-21 | Percutaneously deliverable heart valve and methods associated therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190159897A1 true US20190159897A1 (en) | 2019-05-30 |
Family
ID=44542809
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/038,361 Active 2031-07-17 US8361144B2 (en) | 2010-03-01 | 2011-03-01 | Percutaneously deliverable heart valve and methods associated therewith |
US13/723,541 Abandoned US20130123914A1 (en) | 2010-03-01 | 2012-12-21 | Percutaneously deliverable heart valve and methods associated therewith |
US16/265,573 Abandoned US20190159897A1 (en) | 2010-03-01 | 2019-02-01 | Percutaneously Deliverable Heart Valve and Methods Associated Therewith |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/038,361 Active 2031-07-17 US8361144B2 (en) | 2010-03-01 | 2011-03-01 | Percutaneously deliverable heart valve and methods associated therewith |
US13/723,541 Abandoned US20130123914A1 (en) | 2010-03-01 | 2012-12-21 | Percutaneously deliverable heart valve and methods associated therewith |
Country Status (8)
Country | Link |
---|---|
US (3) | US8361144B2 (en) |
EP (2) | EP2542184B1 (en) |
JP (4) | JP5575931B2 (en) |
CN (2) | CN102869320B (en) |
AU (1) | AU2011223708A1 (en) |
CA (1) | CA2800232C (en) |
SG (2) | SG186837A1 (en) |
WO (1) | WO2011109450A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11771544B2 (en) | 2011-05-05 | 2023-10-03 | Symetis Sa | Method and apparatus for compressing/loading stent-valves |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8308797B2 (en) | 2002-01-04 | 2012-11-13 | Colibri Heart Valve, LLC | Percutaneously implantable replacement heart valve device and method of making same |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US8870950B2 (en) | 2009-12-08 | 2014-10-28 | Mitral Tech Ltd. | Rotation-based anchoring of an implant |
US20110300625A1 (en) * | 2010-03-01 | 2011-12-08 | Vela Biosystems Llc | Tissue for prosthetic implants and grafts, and methods associated therewith |
WO2011109450A2 (en) | 2010-03-01 | 2011-09-09 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve and methods associated therewith |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
CN103153384B (en) | 2010-06-28 | 2016-03-09 | 科利柏心脏瓣膜有限责任公司 | For the device of device in the delivery of vascular of chamber |
US11653910B2 (en) | 2010-07-21 | 2023-05-23 | Cardiovalve Ltd. | Helical anchor implantation |
CA2820738C (en) | 2010-12-14 | 2019-01-15 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
US9498317B2 (en) | 2010-12-16 | 2016-11-22 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
US20120172980A1 (en) * | 2011-01-05 | 2012-07-05 | Curia, Inc. | Kits with prosthetic valves formed with isotropic filter screen leaflets and methods thereof |
US9155619B2 (en) | 2011-02-25 | 2015-10-13 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US8795357B2 (en) | 2011-07-15 | 2014-08-05 | Edwards Lifesciences Corporation | Perivalvular sealing for transcatheter heart valve |
CA3097364C (en) | 2011-12-09 | 2023-08-01 | Edwards Lifesciences Corporation | Prosthetic heart valve having improved commissure supports |
EP3281608B1 (en) * | 2012-02-10 | 2020-09-16 | CVDevices, LLC | Medical product comprising a frame and visceral pleura |
US9999501B2 (en) | 2012-04-18 | 2018-06-19 | Medtronic CV Luxembourg S.a.r.l. | Valve prosthesis |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9301835B2 (en) | 2012-06-04 | 2016-04-05 | Edwards Lifesciences Corporation | Pre-assembled bioprosthetic valve and sealed conduit |
CN104780952A (en) | 2012-07-02 | 2015-07-15 | 波士顿科学医学有限公司 | Prosthetic heart valve formation |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US10376360B2 (en) | 2012-07-27 | 2019-08-13 | W. L. Gore & Associates, Inc. | Multi-frame prosthetic valve apparatus and methods |
US10039638B2 (en) | 2012-12-19 | 2018-08-07 | W. L. Gore & Associates, Inc. | Geometric prosthetic heart valves |
US9737398B2 (en) | 2012-12-19 | 2017-08-22 | W. L. Gore & Associates, Inc. | Prosthetic valves, frames and leaflets and methods thereof |
US10966820B2 (en) | 2012-12-19 | 2021-04-06 | W. L. Gore & Associates, Inc. | Geometric control of bending character in prosthetic heart valve leaflets |
US10321986B2 (en) | 2012-12-19 | 2019-06-18 | W. L. Gore & Associates, Inc. | Multi-frame prosthetic heart valve |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US9681952B2 (en) | 2013-01-24 | 2017-06-20 | Mitraltech Ltd. | Anchoring of prosthetic valve supports |
CA2900862C (en) | 2013-02-11 | 2017-10-03 | Cook Medical Technologies Llc | Expandable support frame and medical device |
US9326856B2 (en) | 2013-03-14 | 2016-05-03 | St. Jude Medical, Cardiology Division, Inc. | Cuff configurations for prosthetic heart valve |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
WO2015143611A1 (en) * | 2014-03-24 | 2015-10-01 | 金仕生物科技(常熟)有限公司 | Biological material treating method, and biological material treated by using same |
US10314697B2 (en) | 2014-08-18 | 2019-06-11 | W. L. Gore & Associates, Inc. | Frame with integral sewing cuff for prosthetic valves |
US9827094B2 (en) | 2014-09-15 | 2017-11-28 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with retention elements |
CA3162308A1 (en) | 2015-02-05 | 2016-08-11 | Cardiovalve Ltd. | Prosthetic valve with axially-sliding frames |
US10299915B2 (en) * | 2015-04-09 | 2019-05-28 | Boston Scientific Scimed, Inc. | Synthetic heart valves composed of zwitterionic polymers |
US10314696B2 (en) | 2015-04-09 | 2019-06-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valves having fiber reinforced leaflets |
US10426609B2 (en) | 2015-04-09 | 2019-10-01 | Boston Scientific Scimed, Inc. | Fiber reinforced prosthetic heart valve having undulating fibers |
US10716671B2 (en) | 2015-07-02 | 2020-07-21 | Boston Scientific Scimed, Inc. | Prosthetic heart valve composed of composite fibers |
US10413403B2 (en) | 2015-07-14 | 2019-09-17 | Boston Scientific Scimed, Inc. | Prosthetic heart valve including self-reinforced composite leaflets |
ITUB20152409A1 (en) * | 2015-07-22 | 2017-01-22 | Sorin Group Italia Srl | VALVE SLEEVE FOR VALVULAR PROSTHESIS AND CORRESPONDING DEVICE |
US11026788B2 (en) * | 2015-08-20 | 2021-06-08 | Edwards Lifesciences Corporation | Loader and retriever for transcatheter heart valve, and methods of crimping transcatheter heart valve |
US10350047B2 (en) | 2015-09-02 | 2019-07-16 | Edwards Lifesciences Corporation | Method and system for packaging and preparing a prosthetic heart valve and associated delivery system |
US10357351B2 (en) | 2015-12-04 | 2019-07-23 | Edwards Lifesciences Corporation | Storage assembly for prosthetic valve |
US10299916B2 (en) * | 2016-01-07 | 2019-05-28 | Medtronic Vascular, Inc. | Bioprosthetic tissue repair and reinforcement |
DE202017007326U1 (en) | 2016-01-29 | 2020-10-20 | Neovasc Tiara Inc. | Valve prosthesis to prevent flow obstruction |
US10531866B2 (en) | 2016-02-16 | 2020-01-14 | Cardiovalve Ltd. | Techniques for providing a replacement valve and transseptal communication |
US10130465B2 (en) * | 2016-02-23 | 2018-11-20 | Abbott Cardiovascular Systems Inc. | Bifurcated tubular graft for treating tricuspid regurgitation |
EP3457989B1 (en) | 2016-05-19 | 2021-09-29 | Boston Scientific Scimed, Inc. | Prosthetic valves, valve leaflets and related methods |
US10856975B2 (en) | 2016-08-10 | 2020-12-08 | Cardiovalve Ltd. | Prosthetic valve with concentric frames |
EP3541462A4 (en) | 2016-11-21 | 2020-06-17 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
CN106691631A (en) * | 2017-02-28 | 2017-05-24 | 沛嘉医疗科技(苏州)有限公司 | Integrated transcatheter interventional heart valve prosthesis system |
WO2018200378A1 (en) | 2017-04-25 | 2018-11-01 | Boston Scientific Scimed, Inc. | Biocompatible polyisobutylene-fiber composite materials and methods |
US11246704B2 (en) | 2017-08-03 | 2022-02-15 | Cardiovalve Ltd. | Prosthetic heart valve |
US11793633B2 (en) | 2017-08-03 | 2023-10-24 | Cardiovalve Ltd. | Prosthetic heart valve |
US10888421B2 (en) | 2017-09-19 | 2021-01-12 | Cardiovalve Ltd. | Prosthetic heart valve with pouch |
US10350095B2 (en) * | 2017-08-17 | 2019-07-16 | Incubar, LLC | Prosthetic vascular valve and methods associated therewith |
WO2019036810A1 (en) | 2017-08-25 | 2019-02-28 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
WO2019051476A1 (en) | 2017-09-11 | 2019-03-14 | Incubar, LLC | Conduit vascular implant sealing device for reducing endoleak |
CN111182856B (en) | 2017-09-12 | 2022-04-29 | W.L.戈尔及同仁股份有限公司 | Leaflet frame attachment for prosthetic valves |
CN115024861A (en) | 2017-09-27 | 2022-09-09 | W.L.戈尔及同仁股份有限公司 | Prosthetic valve with mechanically coupled leaflets |
CA3178271A1 (en) | 2017-09-27 | 2019-04-04 | W.L. Gore & Associates, Inc. | Prosthetic valve with expandable frame and associated systems and methods |
CA3078699C (en) | 2017-10-13 | 2023-10-10 | W.L. Gore & Associates, Inc. | Telescoping prosthetic valve and delivery system |
US9895226B1 (en) | 2017-10-19 | 2018-02-20 | Mitral Tech Ltd. | Techniques for use with prosthetic valve leaflets |
CN116236320A (en) * | 2017-10-19 | 2023-06-09 | 安特瑞斯技术公司 | Replacement heart valve with reduced suturing |
JP7227240B2 (en) | 2017-10-31 | 2023-02-21 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | artificial heart valve |
WO2019089135A1 (en) | 2017-10-31 | 2019-05-09 | W. L. Gore & Associates, Inc. | Transcatheter deployment systems and associated methods |
AU2018362079B2 (en) | 2017-10-31 | 2021-09-16 | Edwards Lifesciences Corporation | Medical valve and leaflet promoting tissue ingrowth |
US11154397B2 (en) | 2017-10-31 | 2021-10-26 | W. L. Gore & Associates, Inc. | Jacket for surgical heart valve |
GB201800399D0 (en) | 2018-01-10 | 2018-02-21 | Mitraltech Ltd | Temperature-control during crimping of an implant |
WO2019195860A2 (en) | 2018-04-04 | 2019-10-10 | Vdyne, Llc | Devices and methods for anchoring transcatheter heart valve |
WO2019222755A1 (en) | 2018-05-18 | 2019-11-21 | Admedus Corporation | Inverted heart valve for transcatheter valve replacement |
AU2019269741B2 (en) | 2018-05-18 | 2023-04-27 | Anteris Technologies Corporation | Replacement heart valve assembly with a valve loaded distally from a stent |
CN112203617A (en) | 2018-05-18 | 2021-01-08 | 安特瑞斯技术公司 | Heart valve with furled sealing area |
CN109549761A (en) * | 2018-09-12 | 2019-04-02 | 沛嘉医疗科技(苏州)有限公司 | A kind of bioprosthesis valve and preparation method thereof |
US10779946B2 (en) | 2018-09-17 | 2020-09-22 | Cardiovalve Ltd. | Leaflet-testing apparatus |
US10595994B1 (en) | 2018-09-20 | 2020-03-24 | Vdyne, Llc | Side-delivered transcatheter heart valve replacement |
US11278437B2 (en) | 2018-12-08 | 2022-03-22 | Vdyne, Inc. | Compression capable annular frames for side delivery of transcatheter heart valve replacement |
US11344413B2 (en) | 2018-09-20 | 2022-05-31 | Vdyne, Inc. | Transcatheter deliverable prosthetic heart valves and methods of delivery |
US11071627B2 (en) | 2018-10-18 | 2021-07-27 | Vdyne, Inc. | Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis |
US10321995B1 (en) | 2018-09-20 | 2019-06-18 | Vdyne, Llc | Orthogonally delivered transcatheter heart valve replacement |
US11109969B2 (en) | 2018-10-22 | 2021-09-07 | Vdyne, Inc. | Guidewire delivery of transcatheter heart valve |
US11517428B2 (en) | 2018-11-01 | 2022-12-06 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
USD926322S1 (en) | 2018-11-07 | 2021-07-27 | W. L. Gore & Associates, Inc. | Heart valve cover |
CA3118599A1 (en) | 2018-11-08 | 2020-05-14 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
US11253359B2 (en) | 2018-12-20 | 2022-02-22 | Vdyne, Inc. | Proximal tab for side-delivered transcatheter heart valves and methods of delivery |
US11185409B2 (en) | 2019-01-26 | 2021-11-30 | Vdyne, Inc. | Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis |
US11273032B2 (en) | 2019-01-26 | 2022-03-15 | Vdyne, Inc. | Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis |
US11648109B2 (en) | 2019-02-04 | 2023-05-16 | Medtronic, Inc. | Balloon expandable frame for transcatheter implantation of a cardiac valve prosthesis |
EP3693030A1 (en) | 2019-02-07 | 2020-08-12 | P+F Products + Features GmbH | Method for preparing biological tissue for surgical implantation |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
CN113543750A (en) | 2019-03-05 | 2021-10-22 | 维迪内股份有限公司 | Tricuspid valve regurgitation control apparatus for orthogonal transcatheter heart valve prosthesis |
US11076956B2 (en) | 2019-03-14 | 2021-08-03 | Vdyne, Inc. | Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis |
US11173027B2 (en) | 2019-03-14 | 2021-11-16 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
EP3946163A4 (en) | 2019-04-01 | 2022-12-21 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
AU2020271896B2 (en) | 2019-04-10 | 2022-10-13 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
JP2022530764A (en) | 2019-05-04 | 2022-07-01 | ブイダイン,インコーポレイテッド | Tightening device and method for deploying a laterally delivered artificial heart valve with a native annulus. |
US11771554B2 (en) | 2019-05-17 | 2023-10-03 | Medtronic, Inc. | Supra annular tapered balloon expandable stent for transcatheter implantation of a cardiac valve prosthesis |
EP3972673A4 (en) | 2019-05-20 | 2023-06-07 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
AU2020295566B2 (en) | 2019-06-20 | 2023-07-20 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
CN114599316A (en) | 2019-08-20 | 2022-06-07 | 维迪内股份有限公司 | Delivery and retrieval devices and methods for sidedly deliverable transcatheter prosthetic valves |
WO2021040996A1 (en) | 2019-08-26 | 2021-03-04 | Vdyne, Inc. | Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same |
US20210077253A1 (en) * | 2019-09-12 | 2021-03-18 | Boston Scientific Limited | Tissue based bioprosthetic heart valve |
US11234813B2 (en) | 2020-01-17 | 2022-02-01 | Vdyne, Inc. | Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery |
EP4157368A2 (en) * | 2020-05-29 | 2023-04-05 | Medtronic, Inc. | Assemblies including a pre-loaded implant and methods of sterilizing assemblies |
CN111686304A (en) * | 2020-06-11 | 2020-09-22 | 四川大学 | Small-size transcatheter artificial heart valve and preparation method thereof |
US20230248513A1 (en) | 2020-07-07 | 2023-08-10 | Anteris Technologies Corporation | Expandable frame for improved hemodynamic performance of transcatheter replacement heart valve |
CN114052004A (en) * | 2020-07-30 | 2022-02-18 | 赛诺心畅医疗科技有限公司 | Tissue fixation treatment device and operation method thereof |
US20240033077A1 (en) * | 2020-10-01 | 2024-02-01 | The Medical College Of Wisconsin, Inc. | Foldable Prosthetic Heart Valve |
EP4199859A1 (en) * | 2020-11-13 | 2023-06-28 | P+F Products + Features GmbH | Self-expandable stent and set of stents |
EP4046601A1 (en) * | 2021-02-18 | 2022-08-24 | P+F Products + Features GmbH | Mitral stent |
EP4046602A1 (en) * | 2021-02-18 | 2022-08-24 | P+F Products + Features GmbH | Self-extendable stent for pulmonary artery |
EP4046600A1 (en) * | 2021-02-18 | 2022-08-24 | P+F Products + Features GmbH | Aortic stent |
US11622853B1 (en) | 2022-09-30 | 2023-04-11 | Anteris Technologies Corporation | Prosthetic heart valves |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229394A1 (en) * | 2002-06-06 | 2003-12-11 | Ogle Matthew F. | Processed tissue for medical device formation |
Family Cites Families (293)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3014024A (en) | 1958-03-19 | 1961-12-19 | Johnson & Johnson | Collagen film |
US3105492A (en) | 1958-10-01 | 1963-10-01 | Us Catheter & Instr Corp | Synthetic blood vessel grafts |
US3029819A (en) | 1959-07-30 | 1962-04-17 | J L Mcatee | Artery graft and method of producing artery grafts |
US3320972A (en) | 1964-04-16 | 1967-05-23 | Roy F High | Prosthetic tricuspid valve and method of and device for fabricating same |
US3409914A (en) | 1966-07-01 | 1968-11-12 | Avco Corp | Connector for blood pumps and the like |
AT261800B (en) | 1966-08-22 | 1968-05-10 | Braun Internat Gmbh B | Process for the manufacture of tubular, smooth or threaded tissue-blood vessel prostheses |
US3548417A (en) | 1967-09-05 | 1970-12-22 | Ronnie G Kischer | Heart valve having a flexible wall which rotates between open and closed positions |
US3588920A (en) | 1969-09-05 | 1971-06-29 | Sigmund A Wesolowski | Surgical vascular prostheses formed of polyester fiber paper |
US3671979A (en) | 1969-09-23 | 1972-06-27 | Univ Utah | Catheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve |
US3878565A (en) | 1971-07-14 | 1975-04-22 | Providence Hospital | Vascular prosthesis with external pile surface |
US3945052A (en) | 1972-05-01 | 1976-03-23 | Meadox Medicals, Inc. | Synthetic vascular graft and method for manufacturing the same |
US4291420A (en) | 1973-11-09 | 1981-09-29 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Artificial heart valve |
US3986828A (en) | 1974-03-05 | 1976-10-19 | Meadox Medicals, Inc. | Polymer fabric compacting process |
US3966401A (en) | 1974-07-01 | 1976-06-29 | Hancock Laboratories Incorporated | Preparing natural tissue for implantation so as to provide improved flexibility |
US4340091A (en) * | 1975-05-07 | 1982-07-20 | Albany International Corp. | Elastomeric sheet materials for heart valve and other prosthetic implants |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4035849A (en) | 1975-11-17 | 1977-07-19 | William W. Angell | Heart valve stent and process for preparing a stented heart valve prosthesis |
US4084268A (en) | 1976-04-22 | 1978-04-18 | Shiley Laboratories, Incorporated | Prosthetic tissue heart valve |
US4082507A (en) | 1976-05-10 | 1978-04-04 | Sawyer Philip Nicholas | Prosthesis and method for making the same |
US4056854A (en) | 1976-09-28 | 1977-11-08 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Aortic heart valve catheter |
DK229077A (en) | 1977-05-25 | 1978-11-26 | Biocoating Aps | HEARTBALL PROSTHET AND PROCEDURE FOR MANUFACTURING IT |
US4164045A (en) | 1977-08-03 | 1979-08-14 | Carbomedics, Inc. | Artificial vascular and patch grafts |
US4172295A (en) | 1978-01-27 | 1979-10-30 | Shiley Scientific, Inc. | Tri-cuspid three-tissue prosthetic heart valve |
US4265694A (en) | 1978-12-14 | 1981-05-05 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Method of making unitized three leaflet heart valve |
US4222126A (en) | 1978-12-14 | 1980-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health, Education & Welfare | Unitized three leaflet heart valve |
US4388735A (en) | 1980-11-03 | 1983-06-21 | Shiley Inc. | Low profile prosthetic xenograft heart valve |
DE3042860A1 (en) | 1980-11-13 | 1982-06-09 | Heyl & Co Chemisch-Pharmazeutische Fabrik, 1000 Berlin | COLLAGEN PREPARATIONS, METHODS FOR THEIR PRODUCTION AND THEIR USE IN HUMAN AND VETERINE MEDICINE |
US4350492A (en) | 1981-08-24 | 1982-09-21 | Vascor, Inc. | Method for preparing tissue heart valve |
US4364127A (en) | 1981-10-02 | 1982-12-21 | Research Corporation | Trileaflet type prosthetic heart valve |
GR77865B (en) | 1982-03-25 | 1984-09-25 | Coats Ltd J & P | |
US4473423A (en) | 1982-05-03 | 1984-09-25 | University Of Utah | Artificial heart valve made by vacuum forming technique |
US4456589A (en) | 1982-07-08 | 1984-06-26 | Genetic Laboratories, Inc. | Preparation of animal tissues for surgical implantation in human recipients |
US4517687A (en) | 1982-09-15 | 1985-05-21 | Meadox Medicals, Inc. | Synthetic woven double-velour graft |
US4477930A (en) | 1982-09-28 | 1984-10-23 | Mitral Medical International, Inc. | Natural tissue heat valve and method of making same |
US4801299A (en) | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
US4631052A (en) | 1984-01-03 | 1986-12-23 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4627436A (en) | 1984-03-01 | 1986-12-09 | Innoventions Biomedical Inc. | Angioplasty catheter and method for use thereof |
IT1208326B (en) | 1984-03-16 | 1989-06-12 | Sorin Biomedica Spa | CARDIAC VALVE PROSTHESIS PROVIDED WITH VALVES OF ORGANIC FABRIC |
US4979939A (en) | 1984-05-14 | 1990-12-25 | Surgical Systems & Instruments, Inc. | Atherectomy system with a guide wire |
US5007896A (en) | 1988-12-19 | 1991-04-16 | Surgical Systems & Instruments, Inc. | Rotary-catheter for atherectomy |
US4883458A (en) | 1987-02-24 | 1989-11-28 | Surgical Systems & Instruments, Inc. | Atherectomy system and method of using the same |
US4728328A (en) | 1984-10-19 | 1988-03-01 | Research Corporation | Cuffed tubular organic prostheses |
US4759758A (en) | 1984-12-07 | 1988-07-26 | Shlomo Gabbay | Prosthetic heart valve |
US4600533A (en) | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
US4798611A (en) | 1986-10-14 | 1989-01-17 | Hancock Jaffe Laboratories | Enhancement of xenogeneic tissue |
IT1202558B (en) | 1987-02-17 | 1989-02-09 | Alberto Arpesani | INTERNAL PROSTHESIS FOR THE REPLACEMENT OF A PART OF THE HUMAN BODY PARTICULARLY IN THE VASCULAR OPERATIONS |
US4870966A (en) | 1988-02-01 | 1989-10-03 | American Cyanamid Company | Bioabsorbable surgical device for treating nerve defects |
US4976733A (en) | 1988-02-03 | 1990-12-11 | Biomedical Design, Inc. | Prevention of prosthesis calcification |
US4892539A (en) | 1988-02-08 | 1990-01-09 | D-R Medical Systems, Inc. | Vascular graft |
US5746775A (en) | 1988-04-01 | 1998-05-05 | The Board Of Regent6S Of The University Of Michigan | Method of making calcification-resistant bioprosthetic tissue |
US5032128A (en) | 1988-07-07 | 1991-07-16 | Medtronic, Inc. | Heart valve prosthesis |
US5011488A (en) | 1988-12-07 | 1991-04-30 | Robert Ginsburg | Thrombus extraction system |
US5171273A (en) | 1989-01-13 | 1992-12-15 | University Of Medicine And Dentistry Of New Jersey | Synthetic collagen orthopaedic structures such as grafts, tendons and other structures |
US4966604A (en) | 1989-01-23 | 1990-10-30 | Interventional Technologies Inc. | Expandable atherectomy cutter with flexibly bowed blades |
US5047041A (en) | 1989-08-22 | 1991-09-10 | Samuels Peter B | Surgical apparatus for the excision of vein valves in situ |
US5413601A (en) | 1990-03-26 | 1995-05-09 | Keshelava; Viktor V. | Tubular organ prosthesis |
US5080660A (en) | 1990-05-11 | 1992-01-14 | Applied Urology, Inc. | Electrosurgical electrode |
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5360443A (en) | 1990-06-11 | 1994-11-01 | Barone Hector D | Aortic graft for repairing an abdominal aortic aneurysm |
US5578071A (en) | 1990-06-11 | 1996-11-26 | Parodi; Juan C. | Aortic graft |
IT9084979A1 (en) | 1990-07-30 | 1992-01-31 | Imad Sheiban | PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTIC CATHETER WITH TWO BALLOONS AT ITS DISTAL END ONE OF SMALL DIAMETER (1, 5MM. FOLLOWED BY ANOTHER BALLOON OF GREATER DIAMETER VARIABLE FROM 2, 5 TO 4 MM THE BALLOON THE SMALL BALLOON |
US5549664A (en) | 1990-07-31 | 1996-08-27 | Ube Industries, Ltd. | Artificial blood vessel |
US5139515A (en) | 1990-08-15 | 1992-08-18 | Francis Robicsek | Ascending aortic prosthesis |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5052771A (en) | 1990-12-21 | 1991-10-01 | Eastman Kodak Company | Integrated electro-optical scanner |
US5163955A (en) | 1991-01-24 | 1992-11-17 | Autogenics | Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment |
EP0571527B1 (en) | 1991-02-14 | 1996-04-24 | Baxter International Inc. | Method of manufacturing pliable biological graft materials |
US5282847A (en) | 1991-02-28 | 1994-02-01 | Medtronic, Inc. | Prosthetic vascular grafts with a pleated structure |
BR9206005A (en) | 1991-05-16 | 1994-08-02 | Mures Cardiovascular Research | Heart valve, process to form an artificial heart valve, flexible tissue for the formation of a heart valve, and, set to form trapezoidal pericardial membranes for the formation of a heart valve |
IT1245750B (en) | 1991-05-24 | 1994-10-14 | Sorin Biomedica Emodialisi S R | CARDIAC VALVE PROSTHESIS, PARTICULARLY FOR REPLACING THE AORTIC VALVE |
US5374539A (en) | 1991-06-17 | 1994-12-20 | Nimni; Marcel E. | Process for purifying collagen and generating bioprosthesis |
US6029671A (en) | 1991-07-16 | 2000-02-29 | Heartport, Inc. | System and methods for performing endovascular procedures |
US5203328A (en) | 1991-07-17 | 1993-04-20 | Georgia Tech Research Corporation | Apparatus and methods for quantitatively measuring molecular changes in the ocular lens |
US5522879A (en) | 1991-11-12 | 1996-06-04 | Ethicon, Inc. | Piezoelectric biomedical device |
US5316023A (en) | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
US5383927A (en) | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US5332402A (en) | 1992-05-12 | 1994-07-26 | Teitelbaum George P | Percutaneously-inserted cardiac valve |
US5261878A (en) | 1992-05-19 | 1993-11-16 | The Regents Of The University Of California | Double balloon pediatric ductus arteriosus stent catheter and method of using the same |
US7213601B2 (en) | 1993-02-22 | 2007-05-08 | Heartport, Inc | Minimally-invasive devices and methods for treatment of congestive heart failure |
US20020029783A1 (en) | 1993-02-22 | 2002-03-14 | Stevens John H. | Minimally-invasive devices and methods for treatment of congestive heart failure |
US6010531A (en) | 1993-02-22 | 2000-01-04 | Heartport, Inc. | Less-invasive devices and methods for cardiac valve surgery |
US5972030A (en) | 1993-02-22 | 1999-10-26 | Heartport, Inc. | Less-invasive devices and methods for treatment of cardiac valves |
US6125852A (en) | 1993-02-22 | 2000-10-03 | Heartport, Inc. | Minimally-invasive devices and methods for treatment of congestive heart failure |
EP0680733B1 (en) | 1993-08-20 | 2003-01-15 | Kanji Inoue | Implant and method of collapsing it |
US5713950A (en) | 1993-11-01 | 1998-02-03 | Cox; James L. | Method of replacing heart valves using flexible tubes |
US5480424A (en) | 1993-11-01 | 1996-01-02 | Cox; James L. | Heart valve replacement using flexible tubes |
DE4340072C2 (en) | 1993-11-24 | 1996-05-15 | Siemens Ag | Device for examining tissue with light |
US5509930A (en) | 1993-12-17 | 1996-04-23 | Autogenics | Stentless heart valve |
US5476506A (en) | 1994-02-08 | 1995-12-19 | Ethicon, Inc. | Bi-directional crimped graft |
US5522881A (en) | 1994-06-28 | 1996-06-04 | Meadox Medicals, Inc. | Implantable tubular prosthesis having integral cuffs |
CA2147547C (en) | 1994-08-02 | 2006-12-19 | Peter J. Schmitt | Thinly woven flexible graft |
DE4430485C1 (en) | 1994-08-27 | 1996-03-07 | Braun B Surgical Gmbh | Textile vascular prosthesis, process for its manufacture and tools for its manufacture |
US5549666A (en) | 1994-09-02 | 1996-08-27 | Baxter International Inc. | Natural tissue valve prostheses having variably complaint leaflets |
US5545215A (en) | 1994-09-14 | 1996-08-13 | Duran; Carlos G. | External sigmoid valve complex frame and valved conduit supported by the same |
US5733299A (en) | 1994-10-20 | 1998-03-31 | Cordis Corporation | Two balloon catheter |
CA2163708C (en) | 1994-12-07 | 2007-08-07 | Robert E. Fischell | Integrated dual-function catheter system for balloon angioplasty and stent delivery |
EP0813397A4 (en) | 1995-03-10 | 1999-10-06 | Cardiovascular Concepts Inc | Tubular endoluminar prosthesis having oblique ends |
BE1009278A3 (en) | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as. |
WO1996036297A1 (en) | 1995-05-19 | 1996-11-21 | Kanji Inoue | Transplantation instrument, method of bending same and method of transplanting same |
US5728152A (en) | 1995-06-07 | 1998-03-17 | St. Jude Medical, Inc. | Bioresorbable heart valve support |
US5861028A (en) | 1996-09-09 | 1999-01-19 | Shelhigh Inc | Natural tissue heart valve and stent prosthesis and method for making the same |
GB2312485B (en) | 1996-04-24 | 1999-10-20 | Endre Bodnar | Bioprosthetic conduits |
US5855601A (en) | 1996-06-21 | 1999-01-05 | The Trustees Of Columbia University In The City Of New York | Artificial heart valve and method and device for implanting the same |
TW501934B (en) | 1996-11-20 | 2002-09-11 | Tapic Int Co Ltd | Collagen material and process for making the same |
US5782914A (en) | 1996-11-29 | 1998-07-21 | Bio-Vascular, Inc. | Method for preparing heterogeneous tissue grafts |
JP2001505807A (en) * | 1996-12-10 | 2001-05-08 | パーデュー・リサーチ・ファウンデーション | Artificial vascular valve |
AU743779B2 (en) | 1996-12-10 | 2002-02-07 | Cook Biotech, Inc. | Tubular grafts from purified submucosa |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
US5961539A (en) | 1997-01-17 | 1999-10-05 | Segmed, Inc. | Method and apparatus for sizing, stabilizing and/or reducing the circumference of an anatomical structure |
US5928281A (en) | 1997-03-27 | 1999-07-27 | Baxter International Inc. | Tissue heart valves |
US5961549A (en) | 1997-04-03 | 1999-10-05 | Baxter International Inc. | Multi-leaflet bioprosthetic heart valve |
WO1998046165A1 (en) | 1997-04-11 | 1998-10-22 | Cryolife, Inc. | Tissue decellularization |
US5957949A (en) | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
US6162245A (en) | 1997-05-07 | 2000-12-19 | Iowa-India Investments Company Limited | Stent valve and stent graft |
DE19721902A1 (en) | 1997-05-26 | 1998-12-03 | Boehringer Mannheim Gmbh | Method and device for in-vivo detection of the direction of Langer lines in the skin |
US6409755B1 (en) | 1997-05-29 | 2002-06-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6004328A (en) | 1997-06-19 | 1999-12-21 | Solar; Ronald J. | Radially expandable intraluminal stent and delivery catheter therefore and method of using the same |
CA2264561C (en) | 1997-06-27 | 2013-04-09 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for circulatory valve repair |
ATE286687T1 (en) | 1997-07-17 | 2005-01-15 | Schneider Europ Gmbh | STENT AND PRODUCTION METHOD THEREOF |
US7039446B2 (en) | 2001-01-26 | 2006-05-02 | Sensys Medical, Inc. | Indirect measurement of tissue analytes through tissue properties |
US5925063A (en) | 1997-09-26 | 1999-07-20 | Khosravi; Farhad | Coiled sheet valve, filter or occlusive device and methods of use |
US6091984A (en) | 1997-10-10 | 2000-07-18 | Massachusetts Institute Of Technology | Measuring tissue morphology |
US5862806A (en) | 1997-10-30 | 1999-01-26 | Mitroflow International, Inc. | Borohydride reduction of biological tissues |
US6174327B1 (en) | 1998-02-27 | 2001-01-16 | Scimed Life Systems, Inc. | Stent deployment apparatus and method |
US6129756A (en) | 1998-03-16 | 2000-10-10 | Teramed, Inc. | Biluminal endovascular graft system |
CA2324958C (en) | 1998-03-23 | 2009-12-22 | Bio-Vascular, Inc. | Pericardial tissue implants and methods of making them |
US7500988B1 (en) | 2000-11-16 | 2009-03-10 | Cordis Corporation | Stent for use in a stent graft |
US6290731B1 (en) | 1998-03-30 | 2001-09-18 | Cordis Corporation | Aortic graft having a precursor gasket for repairing an abdominal aortic aneurysm |
US6352554B2 (en) | 1998-05-08 | 2002-03-05 | Sulzer Vascutek Limited | Prosthetic tubular aortic conduit and method for manufacturing the same |
WO1999058082A2 (en) * | 1998-05-14 | 1999-11-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
AU753773B2 (en) | 1998-06-05 | 2002-10-31 | Organogenesis Inc. | Bioengineered vascular graft prostheses |
DE69940466D1 (en) | 1998-06-05 | 2009-04-09 | Organogenesis Inc | BIOLOGICALLY MODELED IMPLANTABLE PROSTHESIS |
CN1105795C (en) | 1998-06-11 | 2003-04-16 | 清水庆彦 | Collagen material and process for producing the same |
US6630001B2 (en) | 1998-06-24 | 2003-10-07 | International Heart Institute Of Montana Foundation | Compliant dehyrated tissue for implantation and process of making the same |
US6117169A (en) | 1998-06-24 | 2000-09-12 | Sulzer Carbomedics Inc. | Living hinge attachment of leaflet to a valve body |
US6254636B1 (en) | 1998-06-26 | 2001-07-03 | St. Jude Medical, Inc. | Single suture biological tissue aortic stentless valve |
US20030217415A1 (en) | 1998-06-30 | 2003-11-27 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
US6293970B1 (en) | 1998-06-30 | 2001-09-25 | Lifenet | Plasticized bone and soft tissue grafts and methods of making and using same |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6168619B1 (en) | 1998-10-16 | 2001-01-02 | Quanam Medical Corporation | Intravascular stent having a coaxial polymer member and end sleeves |
US6214055B1 (en) | 1998-10-30 | 2001-04-10 | Mures Cardiovascular Research, Inc. | Method and kit for rapid preparation of autologous tissue medical devices |
US6977231B1 (en) | 1999-01-21 | 2005-12-20 | Nipro Corporation | Suturable adhesion-preventing membrane |
US6404497B1 (en) | 1999-01-25 | 2002-06-11 | Massachusetts Institute Of Technology | Polarized light scattering spectroscopy of tissue |
US6736845B2 (en) | 1999-01-26 | 2004-05-18 | Edwards Lifesciences Corporation | Holder for flexible heart valve |
US7018401B1 (en) | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
US6425916B1 (en) | 1999-02-10 | 2002-07-30 | Michi E. Garrison | Methods and devices for implanting cardiac valves |
US6666886B1 (en) | 1999-02-16 | 2003-12-23 | Regents Of The University Of Minnesota | Tissue equivalent approach to a tissue-engineered cardiovascular valve |
US6342069B1 (en) | 1999-03-26 | 2002-01-29 | Mures Cardiovascular Research, Inc. | Surgical instruments utilized to assemble a stentless autologous tissue heart valve |
US6391333B1 (en) | 1999-04-14 | 2002-05-21 | Collagen Matrix, Inc. | Oriented biopolymeric membrane |
US6264691B1 (en) | 1999-04-23 | 2001-07-24 | Shlomo Gabbay | Apparatus and method for supporting a heart valve |
US6287335B1 (en) | 1999-04-26 | 2001-09-11 | William J. Drasler | Intravascular folded tubular endoprosthesis |
US6790229B1 (en) | 1999-05-25 | 2004-09-14 | Eric Berreklouw | Fixing device, in particular for fixing to vascular wall tissue |
US7628803B2 (en) | 2001-02-05 | 2009-12-08 | Cook Incorporated | Implantable vascular device |
US6241763B1 (en) | 1999-06-08 | 2001-06-05 | William J. Drasler | In situ venous valve device and method of formation |
US6312474B1 (en) | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
US6312462B1 (en) | 1999-09-22 | 2001-11-06 | Impra, Inc. | Prosthesis for abdominal aortic aneurysm repair |
US6358275B1 (en) | 1999-10-04 | 2002-03-19 | Sulzer Carbomedics Inc. | Tissue-derived vascular grafts and methods for making the same |
US6383171B1 (en) | 1999-10-12 | 2002-05-07 | Allan Will | Methods and devices for protecting a passageway in a body when advancing devices through the passageway |
US6352708B1 (en) | 1999-10-14 | 2002-03-05 | The International Heart Institute Of Montana Foundation | Solution and method for treating autologous tissue for implant operation |
US6458153B1 (en) | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
US6432712B1 (en) | 1999-11-22 | 2002-08-13 | Bioscience Consultants, Llc | Transplantable recellularized and reendothelialized vascular tissue graft |
US6482240B1 (en) | 1999-12-07 | 2002-11-19 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Method of making a collagen membrane from porcine skin |
US20020128708A1 (en) | 1999-12-09 | 2002-09-12 | Northrup William F. | Annuloplasty system |
US6471723B1 (en) | 2000-01-10 | 2002-10-29 | St. Jude Medical, Inc. | Biocompatible prosthetic tissue |
CA2399905C (en) | 2000-01-14 | 2008-11-18 | Viacor Incorporated | An annuloplasty band |
HUP0204398A2 (en) | 2000-01-27 | 2003-03-28 | 3F Therapeutics | Prosthetic heart valve |
DK1255510T5 (en) | 2000-01-31 | 2009-12-21 | Cook Biotech Inc | Stent Valve Klapper |
US6821297B2 (en) * | 2000-02-02 | 2004-11-23 | Robert V. Snyders | Artificial heart valve, implantation instrument and method therefor |
US6378221B1 (en) | 2000-02-29 | 2002-04-30 | Edwards Lifesciences Corporation | Systems and methods for mapping and marking the thickness of bioprosthetic sheet |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US20020005073A1 (en) | 2000-04-20 | 2002-01-17 | David Tompkins | Method and apparatus for testing the strength of autologous tissue |
US6610088B1 (en) * | 2000-05-03 | 2003-08-26 | Shlomo Gabbay | Biologically covered heart valve prosthesis |
CN1184718C (en) * | 2000-05-23 | 2005-01-12 | 松下电器产业株式会社 | Dielectric medium resonant filter and unnecessary mode and inhibiting method |
US6565960B2 (en) | 2000-06-01 | 2003-05-20 | Shriners Hospital Of Children | Polymer composite compositions |
US6840246B2 (en) | 2000-06-20 | 2005-01-11 | University Of Maryland, Baltimore | Apparatuses and methods for performing minimally invasive diagnostic and surgical procedures inside of a beating heart |
DE60132005T2 (en) | 2000-06-23 | 2008-12-04 | Viacor Inc., Wilmington | AUTOMATIC WRINKLE FOLDING FOR MITRAL LAPPEN REPAIR |
US20020073359A1 (en) | 2000-09-08 | 2002-06-13 | Wade Jennifer A. | System and method for high priority machine check analysis |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
US6913608B2 (en) | 2000-10-23 | 2005-07-05 | Viacor, Inc. | Automated annular plication for mitral valve repair |
US6482228B1 (en) | 2000-11-14 | 2002-11-19 | Troy R. Norred | Percutaneous aortic valve replacement |
US6494909B2 (en) | 2000-12-01 | 2002-12-17 | Prodesco, Inc. | Endovascular valve |
US6696074B2 (en) | 2000-12-04 | 2004-02-24 | Tei Biosciences, Inc. | Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering |
AUPR217300A0 (en) | 2000-12-20 | 2001-01-25 | Ketharanathan, Vettivetpillai | Method of creating biological and biosynthetic material for implantation |
US20020091441A1 (en) | 2001-01-05 | 2002-07-11 | Guzik Donald S. | Focused beam cutting of materials |
WO2002074201A1 (en) | 2001-03-16 | 2002-09-26 | Mayo Foundation For Medical Education And Research | Synthethic leaflets for heart valve repair or replacement |
US6773456B1 (en) | 2001-03-23 | 2004-08-10 | Endovascular Technologies, Inc. | Adjustable customized endovascular graft |
DK1245202T3 (en) | 2001-03-27 | 2004-08-30 | Cook William Europ | Aortic device |
GB0107910D0 (en) | 2001-03-29 | 2001-05-23 | Isis Innovation | Deployable stent |
US7526112B2 (en) | 2001-04-30 | 2009-04-28 | Chase Medical, L.P. | System and method for facilitating cardiac intervention |
US7510571B2 (en) | 2001-06-11 | 2009-03-31 | Boston Scientific, Scimed, Inc. | Pleated composite ePTFE/textile hybrid covering |
WO2003007795A2 (en) * | 2001-07-16 | 2003-01-30 | Edwards Lifesciences Corporation | Tissue engineered heart valve |
US20060025800A1 (en) | 2001-09-05 | 2006-02-02 | Mitta Suresh | Method and device for surgical ventricular repair |
US6961123B1 (en) | 2001-09-28 | 2005-11-01 | The Texas A&M University System | Method and apparatus for obtaining information from polarization-sensitive optical coherence tomography |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US20060020336A1 (en) | 2001-10-23 | 2006-01-26 | Liddicoat John R | Automated annular plication for mitral valve repair |
US20030078659A1 (en) | 2001-10-23 | 2003-04-24 | Jun Yang | Graft element |
US7201771B2 (en) | 2001-12-27 | 2007-04-10 | Arbor Surgical Technologies, Inc. | Bioprosthetic heart valve |
US8308797B2 (en) | 2002-01-04 | 2012-11-13 | Colibri Heart Valve, LLC | Percutaneously implantable replacement heart valve device and method of making same |
US20030130729A1 (en) | 2002-01-04 | 2003-07-10 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
US6764510B2 (en) | 2002-01-09 | 2004-07-20 | Myocor, Inc. | Devices and methods for heart valve treatment |
US7018404B2 (en) | 2002-01-24 | 2006-03-28 | St. Jude Medical, Inc. | Conduit for aorta or pulmonary artery replacement |
US7125418B2 (en) * | 2002-04-16 | 2006-10-24 | The International Heart Institute Of Montana Foundation | Sigmoid valve and method for its percutaneous implantation |
AU2003234505A1 (en) | 2002-05-03 | 2003-11-17 | The General Hospital Corporation | Involuted endovascular valve and method of construction |
US7011688B2 (en) | 2002-05-10 | 2006-03-14 | C.R. Bard, Inc. | Prosthetic repair fabric |
US6736823B2 (en) | 2002-05-10 | 2004-05-18 | C.R. Bard, Inc. | Prosthetic repair fabric |
US7138226B2 (en) | 2002-05-10 | 2006-11-21 | The University Of Miami | Preservation of RNA and morphology in cells and tissues |
US20040024452A1 (en) | 2002-08-02 | 2004-02-05 | Kruse Steven D. | Valved prostheses with preformed tissue leaflets |
US7041132B2 (en) | 2002-08-16 | 2006-05-09 | 3F Therapeutics, Inc, | Percutaneously delivered heart valve and delivery means thereof |
CN1697634A (en) | 2002-09-18 | 2005-11-16 | Sdgi控股股份有限公司 | Natural tissue devices and methods of implantation |
US7062708B2 (en) * | 2002-09-19 | 2006-06-13 | International Business Machines Corporation | Tree construction for XML to XML document transformation |
US7008763B2 (en) | 2002-09-23 | 2006-03-07 | Cheung David T | Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue |
US7402319B2 (en) | 2002-09-27 | 2008-07-22 | Board Of Regents, The University Of Texas System | Cell-free tissue replacement for tissue engineering |
US7189259B2 (en) | 2002-11-26 | 2007-03-13 | Clemson University | Tissue material and process for bioprosthesis |
BRPI0412362A (en) | 2003-07-08 | 2006-09-05 | Ventor Technologies Ltd | prosthetic implant devices particularly for transarterial transport in the treatment of aortic stenoses and implantation methods for such devices |
US6892643B2 (en) * | 2003-07-15 | 2005-05-17 | Special Devices, Inc. | Constant-current, rail-voltage regulated charging electronic detonator |
EP1659992B1 (en) | 2003-07-31 | 2013-03-27 | Cook Medical Technologies LLC | Prosthetic valve devices and methods of making such devices |
US20060259137A1 (en) | 2003-10-06 | 2006-11-16 | Jason Artof | Minimally invasive valve replacement system |
US20050247320A1 (en) | 2003-10-10 | 2005-11-10 | Stack Richard S | Devices and methods for retaining a gastro-esophageal implant |
WO2005042043A2 (en) | 2003-10-28 | 2005-05-12 | Medtronic, Inc. | Methods of preparing crosslinked materials and bioprosthetic devices |
US7232461B2 (en) | 2003-10-29 | 2007-06-19 | Cordis Neurovascular, Inc. | Neck covering device for an aneurysm |
JP2007513083A (en) | 2003-11-10 | 2007-05-24 | アンジオテック インターナショナル アーゲー | Medical implants and fiber inducers |
US7261732B2 (en) * | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
US7329279B2 (en) | 2003-12-23 | 2008-02-12 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
EP2745805B2 (en) * | 2003-12-23 | 2022-05-18 | Boston Scientific Scimed, Inc. | Repositionable heart valve |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US7247167B2 (en) | 2004-02-19 | 2007-07-24 | Shlomo Gabbay | Low profile heart valve prosthesis |
US7289211B1 (en) | 2004-04-09 | 2007-10-30 | Walsh Jr Joseph T | System and method for imaging sub-surface polarization-sensitive material structures |
US7309461B2 (en) | 2004-04-12 | 2007-12-18 | Boston Scientific Scimed, Inc. | Ultrasonic crimping of a varied diameter vascular graft |
US7648676B2 (en) | 2004-04-20 | 2010-01-19 | Rti Biologics, Inc. | Process and apparatus for treating implants comprising soft tissue |
US20050267529A1 (en) | 2004-05-13 | 2005-12-01 | Heber Crockett | Devices, systems and methods for tissue repair |
US7462191B2 (en) | 2004-06-30 | 2008-12-09 | Edwards Lifesciences Pvt, Inc. | Device and method for assisting in the implantation of a prosthetic valve |
US7566343B2 (en) | 2004-09-02 | 2009-07-28 | Boston Scientific Scimed, Inc. | Cardiac valve, system, and method |
US6951571B1 (en) | 2004-09-30 | 2005-10-04 | Rohit Srivastava | Valve implanting device |
WO2006050460A1 (en) * | 2004-10-29 | 2006-05-11 | Cook Incorporated | Vascular valves having implanted and target configurations and methods of preparing the same |
US7771442B2 (en) | 2004-11-22 | 2010-08-10 | Edgar Louis Shriver | Graft core for seal and suture anastomoses with devices and methods for percutaneous intraluminal excisional surgery (PIES) |
EP1838840B1 (en) | 2004-11-22 | 2011-03-09 | Theregen, Inc. | Use of cultured three-dimensional tissue for treating congestive heart failure |
US20060129225A1 (en) | 2004-12-15 | 2006-06-15 | Kopia Gregory A | Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium |
US8874204B2 (en) | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
SG158172A1 (en) | 2004-12-24 | 2010-01-29 | Celxcel Pty Ltd | An implantable biomaterial and a method of producing same |
US20060155366A1 (en) * | 2005-01-10 | 2006-07-13 | Laduca Robert | Apparatus and method for deploying an implantable device within the body |
US7989157B2 (en) | 2005-01-11 | 2011-08-02 | Medtronic, Inc. | Solution for storing bioprosthetic tissue used in a biological prosthesis |
ES2573672T3 (en) | 2005-02-04 | 2016-06-09 | Boston Scientific Scimed Inc. | Needle design for male sling transobturator |
US7914437B2 (en) | 2005-02-04 | 2011-03-29 | Ams Research Corporation | Transobturator methods for installing sling to treat incontinence, and related devices |
ITTO20050074A1 (en) | 2005-02-10 | 2006-08-11 | Sorin Biomedica Cardio Srl | CARDIAC VALVE PROSTHESIS |
EP1850796B1 (en) | 2005-02-18 | 2015-12-09 | The Cleveland Clinic Foundation | Apparatus for replacing a cardiac valve |
WO2006095342A2 (en) | 2005-03-07 | 2006-09-14 | Technion Research & Development Foundation Ltd. | Natural tissue-derived decellularized matrix and methods of generating and using same |
US7462156B2 (en) * | 2005-04-11 | 2008-12-09 | Zan Mitrev | Replacement aortic valve leaflets and related technology |
EP1893131A1 (en) | 2005-04-20 | 2008-03-05 | The Cleveland Clinic Foundation | Apparatus and method for replacing a cardiac valve |
US7164145B2 (en) | 2005-05-12 | 2007-01-16 | Honeywell International Inc. | Measuring fiber orientation by detecting dispersion of polarized light |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
WO2007001351A1 (en) | 2005-06-17 | 2007-01-04 | Iken Tissue Therapeutics, Inc. | Methods for treating ischemic tissue |
US8951285B2 (en) | 2005-07-05 | 2015-02-10 | Mitralign, Inc. | Tissue anchor, anchoring system and methods of using the same |
US8470022B2 (en) | 2005-08-31 | 2013-06-25 | Cook Biotech Incorporated | Implantable valve |
US7712606B2 (en) * | 2005-09-13 | 2010-05-11 | Sadra Medical, Inc. | Two-part package for medical implant |
WO2007035843A2 (en) | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
US20080190989A1 (en) | 2005-10-03 | 2008-08-14 | Crews Samuel T | Endoscopic plication device and method |
US8167932B2 (en) * | 2005-10-18 | 2012-05-01 | Edwards Lifesciences Corporation | Heart valve delivery system with valve catheter |
US20070213813A1 (en) * | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US9717468B2 (en) | 2006-01-10 | 2017-08-01 | Mediguide Ltd. | System and method for positioning an artificial heart valve at the position of a malfunctioning valve of a heart through a percutaneous route |
US20080039871A1 (en) | 2006-04-04 | 2008-02-14 | Wallace Jeffrey M | Minimally invasive gastric restriction methods |
US9005220B2 (en) | 2006-04-04 | 2015-04-14 | C.R. Bard, Inc. | Suturing devices and methods with energy emitting elements |
US8425584B2 (en) * | 2006-04-21 | 2013-04-23 | W. L. Gore & Associates, Inc. | Expandable covered stent with wide range of wrinkle-free deployed diameters |
US7460248B2 (en) | 2006-05-15 | 2008-12-02 | Carestream Health, Inc. | Tissue imaging system |
WO2007138572A2 (en) | 2006-06-01 | 2007-12-06 | Mor Research Applications Ltd. | Methods and devices for treatment of cardiac valves |
US20080009667A1 (en) | 2006-06-08 | 2008-01-10 | Ams Research Corporation | Methods and apparatus for prolapse repair and hysterectomy |
US20080039926A1 (en) | 2006-08-11 | 2008-02-14 | Majercak David C | Stent graft sealing zone connecting structure |
US8876894B2 (en) * | 2006-09-19 | 2014-11-04 | Medtronic Ventor Technologies Ltd. | Leaflet-sensitive valve fixation member |
US8834564B2 (en) * | 2006-09-19 | 2014-09-16 | Medtronic, Inc. | Sinus-engaging valve fixation member |
CA2665209C (en) | 2006-10-03 | 2016-01-05 | Alure Medical, Inc. | Minimally invasive tissue support |
CN103933612B (en) * | 2006-10-27 | 2016-06-22 | 爱德华兹生命科学公司 | Biological tissue for Srgery grafting |
US8070799B2 (en) | 2006-12-19 | 2011-12-06 | Sorin Biomedica Cardio S.R.L. | Instrument and method for in situ deployment of cardiac valve prostheses |
US8105375B2 (en) * | 2007-01-19 | 2012-01-31 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
US8092522B2 (en) | 2007-02-15 | 2012-01-10 | Cook Medical Technologies Llc | Artificial valve prostheses with a free leaflet portion |
US8747458B2 (en) * | 2007-08-20 | 2014-06-10 | Medtronic Ventor Technologies Ltd. | Stent loading tool and method for use thereof |
EP3492043A3 (en) * | 2007-08-21 | 2019-09-04 | Symetis SA | A replacement valve |
US20090062907A1 (en) | 2007-08-31 | 2009-03-05 | Quijano Rodolfo C | Self-expanding valve for the venous system |
WO2009038761A1 (en) * | 2007-09-19 | 2009-03-26 | St. Jude Medical, Inc. | Fiber-reinforced synthetic sheets for prosthetic heart valve leaflets |
WO2009052188A1 (en) | 2007-10-15 | 2009-04-23 | Edwards Lifesciences Corporation | Transcatheter heart valve with micro-anchors |
US8357387B2 (en) * | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
WO2009094373A1 (en) | 2008-01-22 | 2009-07-30 | Cook Incorporated | Valve frame |
US20090254175A1 (en) | 2008-04-03 | 2009-10-08 | Quijano Rodolfo C | Valved stent for chronic venous insufficiency |
WO2009156471A1 (en) | 2008-06-26 | 2009-12-30 | Iberhospitex, S.A. | Prosthetic heart valve and method for making such a valve |
US8763222B2 (en) * | 2008-08-01 | 2014-07-01 | Intersect Ent, Inc. | Methods and devices for crimping self-expanding devices |
US20110208299A1 (en) * | 2008-08-19 | 2011-08-25 | Roelof Marissen | Implantable valve prosthesis and method for manufacturing such a valve |
US8652202B2 (en) * | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US8308798B2 (en) * | 2008-12-19 | 2012-11-13 | Edwards Lifesciences Corporation | Quick-connect prosthetic heart valve and methods |
US8029534B2 (en) | 2009-03-16 | 2011-10-04 | Cook Medical Technologies Llc | Closure device with string retractable umbrella |
US7967138B2 (en) * | 2009-04-06 | 2011-06-28 | Medtronic Vascular, Inc. | Packaging systems for percutaneously deliverable bioprosthetic valves |
CA2760207C (en) * | 2009-04-28 | 2014-08-12 | Dc Devices, Inc. | Devices, systems and methods to treat heart failure |
US20110300625A1 (en) | 2010-03-01 | 2011-12-08 | Vela Biosystems Llc | Tissue for prosthetic implants and grafts, and methods associated therewith |
WO2011109450A2 (en) | 2010-03-01 | 2011-09-09 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve and methods associated therewith |
CN103153384B (en) | 2010-06-28 | 2016-03-09 | 科利柏心脏瓣膜有限责任公司 | For the device of device in the delivery of vascular of chamber |
US9498317B2 (en) * | 2010-12-16 | 2016-11-22 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery systems and packaging |
-
2011
- 2011-03-01 WO PCT/US2011/026763 patent/WO2011109450A2/en active Application Filing
- 2011-03-01 CA CA2800232A patent/CA2800232C/en active Active
- 2011-03-01 EP EP11751242.6A patent/EP2542184B1/en active Active
- 2011-03-01 SG SG2012095758A patent/SG186837A1/en unknown
- 2011-03-01 US US13/038,361 patent/US8361144B2/en active Active
- 2011-03-01 CN CN201180022155.XA patent/CN102869320B/en active Active
- 2011-03-01 EP EP16151844.4A patent/EP3028672A1/en not_active Ceased
- 2011-03-01 JP JP2012556191A patent/JP5575931B2/en not_active Expired - Fee Related
- 2011-03-01 SG SG10201501500TA patent/SG10201501500TA/en unknown
- 2011-03-01 CN CN201610825427.4A patent/CN106943208B/en active Active
- 2011-03-01 AU AU2011223708A patent/AU2011223708A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,541 patent/US20130123914A1/en not_active Abandoned
-
2014
- 2014-07-02 JP JP2014136849A patent/JP2015013119A/en active Pending
-
2016
- 2016-07-22 JP JP2016144286A patent/JP2016195827A/en active Pending
-
2018
- 2018-12-28 JP JP2018247025A patent/JP2019069233A/en active Pending
-
2019
- 2019-02-01 US US16/265,573 patent/US20190159897A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229394A1 (en) * | 2002-06-06 | 2003-12-11 | Ogle Matthew F. | Processed tissue for medical device formation |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11771544B2 (en) | 2011-05-05 | 2023-10-03 | Symetis Sa | Method and apparatus for compressing/loading stent-valves |
Also Published As
Publication number | Publication date |
---|---|
EP2542184A4 (en) | 2014-08-27 |
CN102869320A (en) | 2013-01-09 |
JP2015013119A (en) | 2015-01-22 |
JP2013521060A (en) | 2013-06-10 |
JP2019069233A (en) | 2019-05-09 |
EP3028672A1 (en) | 2016-06-08 |
CN106943208B (en) | 2020-01-24 |
SG10201501500TA (en) | 2015-04-29 |
JP5575931B2 (en) | 2014-08-20 |
CA2800232C (en) | 2015-08-11 |
WO2011109450A3 (en) | 2012-01-05 |
US20110301700A1 (en) | 2011-12-08 |
WO2011109450A2 (en) | 2011-09-09 |
SG186837A1 (en) | 2013-02-28 |
EP2542184B1 (en) | 2016-05-25 |
CA2800232A1 (en) | 2011-09-09 |
US20130123914A1 (en) | 2013-05-16 |
EP2542184A2 (en) | 2013-01-09 |
CN102869320B (en) | 2016-10-12 |
JP2016195827A (en) | 2016-11-24 |
CN106943208A (en) | 2017-07-14 |
US8361144B2 (en) | 2013-01-29 |
AU2011223708A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190159897A1 (en) | Percutaneously Deliverable Heart Valve and Methods Associated Therewith | |
US11628061B2 (en) | Modular valve prosthesis with anchor stent and valve component | |
US9011524B2 (en) | Prosthetic heart valves and methods of attaching same | |
JP2013521060A5 (en) | ||
US10058421B2 (en) | Prosthetic cardiac valve formed from pericardium material and methods of making same | |
CN108652790B (en) | Valve prosthesis and delivery method | |
WO2009156471A1 (en) | Prosthetic heart valve and method for making such a valve | |
AU2018217314B2 (en) | Percutaneously deliverable heart valve and methods associated therewith | |
ES2595358T3 (en) | Heart valve that can be placed percutaneously and associated procedures | |
Rabelo et al. | Aortic valve replacement with the Labcor stentless porcine bioprosthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COLIBRI HEART VALVE LLC, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FISH, R. DAVID;PANIAGUA, DAVID;SIGNING DATES FROM 20110928 TO 20111010;REEL/FRAME:048222/0157 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |